Genetic Consideration of Schizotypal Traits: A Review by Walter, Emma E. et al.
Northumbria Research Link
Citation: Walter, Emma E., Fernandez, Francesca, Snelling, Mollie and Barkus, Emma (2016) Genetic 
Consideration of Schizotypal Traits: A Review. Frontiers in Psychology, 7. p. 1769. ISSN 1664-1078 
Published by: Frontiers Research Foundation
URL: https://doi.org/10.3389/fpsyg.2016.01769 <https://doi.org/10.3389/fpsyg.2016.01769>
This  version  was  downloaded  from  Northumbria  Research  Link: 
http://nrl.northumbria.ac.uk/id/eprint/43813/
Northumbria University has developed Northumbria Research Link (NRL) to enable users to access 
the University’s research output. Copyright © and moral rights for items on NRL are retained by the 
individual author(s) and/or other copyright owners.  Single copies of full items can be reproduced, 
displayed or performed, and given to third parties in any format or medium for personal research or 
study, educational, or not-for-profit purposes without prior permission or charge, provided the authors, 
title and full bibliographic details are given, as well as a hyperlink and/or URL to the original metadata 
page. The content must not be changed in any way. Full items must not be sold commercially in any  
format or medium without formal permission of the copyright holder.  The full policy is available online: 
http://nrl.northumbria.ac.uk/pol  i cies.html  
This  document  may differ  from the  final,  published version of  the research  and has been made 
available online in accordance with publisher policies. To read and/or cite from the published version 
of the research, please visit the publisher’s website (a subscription may be required.)
                        
REVIEW
published: 15 November 2016
doi: 10.3389/fpsyg.2016.01769
Frontiers in Psychology | www.frontiersin.org 1 November 2016 | Volume 7 | Article 1769
Edited by:
Kimberly J. Saudino,
Boston University, USA
Reviewed by:
Jeffrey R. Gagne,
University of Texas at Arlington, USA
Caroline Gurvich,
Monash University, Australia
*Correspondence:
Emma Barkus
ebarkus@uow.edu.au
Specialty section:
This article was submitted to
Personality and Social Psychology,
a section of the journal
Frontiers in Psychology
Received: 17 August 2016
Accepted: 27 October 2016
Published: 15 November 2016
Citation:
Walter EE, Fernandez F, Snelling M
and Barkus E (2016) Genetic
Consideration of Schizotypal Traits: A
Review. Front. Psychol. 7:1769.
doi: 10.3389/fpsyg.2016.01769
Genetic Consideration of Schizotypal
Traits: A Review
Emma E. Walter 1, Francesca Fernandez 2, Mollie Snelling 2 and Emma Barkus 1*
1 School of Psychology, University of Wollongong, Wollongong, NSW, Australia, 2 Illawarra Health and Medical Research
Institute, University of Wollongong, Wollongong, NSW, Australia
Schizotypal traits are of interest and importance in their own right and also have
theoretical and clinical associations with schizophrenia. These traits comprise attenuated
psychotic symptoms, social withdrawal, reduced cognitive capacity, and affective
dysregulation. The link between schizotypal traits and psychotic disorders has long since
been debated. The status of knowledge at this point is such schizotypal traits are a
risk for psychotic disorders, but in and of themselves only confer liability, with other
risk factors needing to be present before a transition to psychosis occurs. Investigation
of schizotypal traits also has the possibility to inform clinical and research pursuits
concerning those who do not make a transition to psychotic disorders. A growing body
of literature has investigated the genetic underpinnings of schizotypal traits. Here, we
review association, family studies and describe genetic disorders where the expression of
schizotypal traits has been investigated. We conducted a thorough review of the existing
literature, with multiple search engines, references, and linked articles being searched
for relevance to the current review. All articles and book chapters in English were
sourced and reviewed for inclusion. Family studies demonstrate that schizotypal traits
are elevated with increasing genetic proximity to schizophrenia and some chromosomal
regions have been associated with schizotypy. Genes associated with schizophrenia
have provided the initial start point for the investigation of candidate genes for schizotypal
traits; neurobiological pathways of significance have guided selection of genes of interest.
Given the chromosomal regions associated with schizophrenia, some genetic disorders
have also considered the expression of schizotypal traits. Genetic disorders considered
all comprise a profile of cognitive deficits and over representation of psychotic disorders
compared to the general population. We conclude that genetic variations associated
with schizotypal traits require further investigation, perhaps with targeted phenotypes
narrowed to assist in refining the clinical end point of significance.
Keywords: polymorphisms, schizotypy, schizophrenia, psychosis risk, genetic disorders, family studies
INTRODUCTION
Schizotypal personality comprises stable behaviors characterized by persistent attenuated psychotic
symptoms. These include unusual perceptual experiences, odd beliefs, unusual speech (in tone,
intonation, or use of specific words), social anxiety, suspiciousness/paranoia, and isolated fully
formed psychotic symptoms. The rate of clinically diagnosed schizotypal personality disorder
(SPD) is approximately 4% in the general population (Pulay et al., 2009). Differentiation between
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schizotypal traits and SPD reflects the degree of self-recognized
impairment to occupational and interpersonal functioning,
frequency, and severity of symptom presentation. There are an
increasing number of studies suggesting detectable reductions in
interpersonal and occupational functioning in those displaying
schizotypal traits (e.g., Waldeck and Miller, 2000; McGurk
et al., 2013). When used as a screen in the general population,
schizotypal traits are associated with depression, bipolar and
affective and non-affective psychotic disorders longitudinally
(e.g., Miller et al., 2002; Kwapil et al., 2013). Progression rates
from SPD to a psychotic disorder are approximately 40% over
2 years (Nordentoft et al., 2006), double the risk reported in more
recent studies concerned with transition from an at risk mental
state (ARMS) (Fusar-Poli et al., 2013). Clinically, schizotypal
traits are part of the prodrome or ARMS criteria (e.g., Salokangas
and McGlashan, 2008) and SPD has now been moved from
personality disorders into the Schizophrenia Spectrum andOther
Psychotic Disorders section of Diagnostic and Statistical manual
ofMental Disorders (DSM-V; American Psychiatric Association.,
2013). The factors which determine whether someone moves
from non-clinical schizotypal traits to the longitudinal expression
of a clinical disorder are as yet unknown.
As well as the clinical presentation of SPD, researchers and
clinicians are becoming increasingly interested in the expression
of schizotypal traits or schizotypy in the general population.
Clinical psychotic disorders are etiologically complex. Genetic
heritability of schizotypy has been estimated around 30 to 50%
within families (Claridge and Hewitt, 1987; Kendler and Hewitt,
1992; Kendler et al., 1993; Cardno et al., 1999; Chang et al.,
2002; Linney et al., 2003; Macar et al., 2012). Similarly to
schizophrenia susceptibility, schizotypy seems to be polygenic,
with each gene likely conferring only a small to moderate risk,
and interacting against background environmental factors (Grant
et al., 2013; Brambilla et al., 2014). This level of complexity
leads to the hypothesis that the same biological factors that
underpin schizotypy in the general population are also relevant
to more severe clinical disorders such as SPD and psychotic
disorders. The so-called psychosis continuum suggests that risk
factors for psychotic disorders will operate in a similar manner
in subclinical schizotypy as in the clinical end points. Given
that clinical psychotic disorders conceivably occur after a cascade
and interaction between multiple biological, environmental,
and psychological factors, investigating the effects of psychosis-
risk-factors in subclinical schizotypes provides a window into
etiological factors prior to disease progression.
During the last decade, a growing literature has emerged
identifying genetic markers associated with schizotypy. We
will outline the evidence for the proximity of schizotypal
traits to genetic liability for psychotic disorders reporting
notable specific genetic markers, such as single nucleotide
polymorphisms (SNPs), associated with schizotypal traits. These
studies provide evidence for population level variations in genetic
bases underpinning the expression of schizotypal traits. The
few linkage studies which have investigated the chromosomal
regions conferring liability for schizotypal traits within families
will be outlined. Collectively, these studies will delineate
the evidence for schizotypal traits demonstrating heritability
and co-occurrence with schizophrenia. Next, there are some
genetic disorders which report rates of psychotic disorders
with higher prevalence than the general population. These
disorders encompass chromosomal regions which are of interest
in schizophrenia. Consideration will be given to genetic disorders
where expressions of schizotypal traits have been reported. These
genetic disorders have well characterized genomic abnormalities
and therefore further assist in pointing to chromosomal regions
of significance for schizotypal trait expression.
We conducted a thorough search in the selection of articles
for the current paper. We made use of PubMed, Scopus, Web
of Science, PsycINFO, and Medline for the identification of
articles. Key search terms were generated on the basis of the
main concepts within each section, and the key words have been
included in parenthesis after subsequent subheadings. All articles
available in English were reviewed for inclusion. We excluded
studies which considered psychotic experiences in subclinical
populations, or who considered psychotic experiences after an
event (e.g., stress, cannabis use). We also excluded studies
which had considered the expression of schizotypal traits in the
presence of bipolar risk. There is substantial debate considering
the relationship between psychotic disorders and bipolar disorder
which is worthy of a review in itself in order to do it justice. These
publications (Mahon et al., 2013) were based within the debate of
this relationship and were therefore not included in the current
articles. For each section, references and similar articles were
then searched to determine whether references had been missed.
This was particularly relevant to the section on Schizotypal Traits
and Genetic Disorders because this represented a small body
of literature. Our last search of the literature was conducted in
August 2016.
HERITABILITY AND LINKAGE STUDIES
FOR SCHIZOTYPAL TRAITS
Expression of Schizotypal Traits in Families
(Schizotypy, Schizotypal, Psychosis,
Psychotic, Family, Familial, Relatives,
Siblings, Twins, Parental)
The expression of schizotypal traits in relatives of patients with
schizophrenia presents the opportunity to investigate whether
schizotypal traits are an intermediate phenotype (Lenzenweger,
2013) for psychotic disorders. Intermediate phenotypes are
heritable and underpinned by biological mechanisms. They lie
between the biological risk and disease end point of interest;
in this case schizotypal traits are predominantly considered for
their relevance for psychosis risk. An intermediate phenotype
is thought to lie mid-distance between genetic risk and the
clinical end point of interest. Unsurprisingly, given we make
this assumption about schizotypal traits, predisposition to
schizophrenia spectrum disorders is considered to be highly
heritable, demonstrated through patterns of risk in twins, and
other relatives (Tsuang, 2000; Nguyen et al., 2003). First degree
relatives presumably have some of the risk genes since they are
at a 10-fold increased risk for developing the disorder and share
approximately fifty per cent of their genes with their proband
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relatives. Our goal was to identify whether consistent findings
pointed to a reliable relationship between familial liability and
schizotypal expression. The results of schizotypal traits expressed
in non-psychotic relatives of schizophrenia spectrum patients
are summarized in Table 1. Preliminary findings from family
studies suggest a relationship between familial-genetic liability
for schizophrenia and schizotypal traits. Schizotypy has been
implicated as a key expression of risk in the relationship between
familial liability and schizophrenia (Lenzenweger, 2006).
However, it is important to understand whether genetic
factors alone drive elevated rates of schizotypal traits in relatives
of patients with psychotic disorders. To date there are no
methodologically sound population studies (with large sample
sizes, controls for confounds, and for the direction of the
relationship) that explore this association. There are however
two studies that prospectively examine this relationship on a
smaller level (Mata et al., 2000, 2003). The first published in
2000, interviewed mothers of 90 patients with schizophrenia
and 121 of their psychiatrically healthy relatives with the
Present State Examination (PSE; Wing et al., 1974). The authors
were interested in childhood personality, social adjustment of
the mothers, and schizotypal traits in relatives as assessed by
the Kings Schizotypy Questionnaire (KSQ; Williams, 1993),
International Personality Disorder Examination (IPDE; World
Health Organization., 1992) and Venables’ Survey of Attitudes
and Experiences Scale (SAE; Venables et al., 1990). Positive
syndrome in patients was correlated with greater scores for
relatives on the three schizotypy scales; however patient
syndromes did not have a relationship with their corresponding
schizotypal trait (i.e., positive schizotypy to positive syndrome
in patients). The second study published in 2003 sought
to elucidate the link between schizotypal traits in relatives
and psychopathological syndromes in patients with psychoses.
Interviews were conducted with 172 patients admitted with
psychosis (using the PSE) and 263 of their psychiatrically
healthy relatives (using the SAE, KSQ, and IPDE). Schneiderian
symptoms in patients were related to higher scores on both
positive and negative schizotypal features in relatives.
These studies collectively point to schizotypal traits being
highly expressed in relatives of patients with psychotic disorders.
There is one point of limitation which needs to be kept in
mind for studies where parent-child dyads are used in research.
Given that we do not understand the heritability of schizophrenia
risk, it is not possible to be certain that the parent conferring
the genetic risk is included in the study (unless of course
they have a diagnosed psychotic disorder themselves). This
may potentially lead to weakened associations between relative
dyads for schizotypal traits. Indeed, consideration needs to
be given to second degree relatives and their potential role
in conferring genetic liability for schizotypal traits. A study
which examines schizotypal traits within an extended family,
including multiple generations and first and second degree
relatives, would be interesting to determine where strongest
associations are found between individuals. Although these
studies suggest schizotypal traits are a significant factor in
the genetic risk for psychotic disorders they do not highlight
specific chromosomal regions. The two studies from Mata et al.
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(2000) and Mata et al. (2003), suggest that profiles of symptoms
in patients do not relate to their corresponding subclinical
schizotypal traits, for example positive psychotic symptoms were
specifically associated with positive schizotypal traits. This would
suggest, schizotypal traits provide an overall risk for psychosis,
rather than vulnerability toward subtypes of specific psychotic
symptomatology.
Linkage Studies with Schizotypal Traits
(Schizotypy, Schizotypal, Psychosis,
Psychotic, Family, Familial, Relatives,
Siblings, Twins, Parental, Linkage,
Candidate, Plus Specific Genes
Highlighted by Review of Initial Literature)
Most studies which examine candidate genes involved in
schizotypal genetic susceptibility are based on the results of
previous studies of schizophrenia. Only a few studies have
performed genetic analyses on schizotypy in relatives of patients
with schizophrenia (Kendler et al., 1995; Fogelson et al., 1999;
Bergman et al., 2000; Miller et al., 2002; Mata et al., 2003; Fanous
et al., 2007; Lien et al., 2010). Four of these studies included the
Structured Interview Schizotypy or a modified version of it to
assess schizotypy in tested individuals (Kendler et al., 1995;Miller
et al., 2002; Fanous et al., 2007; Lien et al., 2010). Linkage studies
in families have highlighted chromosomic regions of interest
related to the psychosis continuum. Existing studies suggest that
both schizophrenia and schizotypal traits share some common
chromosome regions (such as 4q, 5q; 6p, 6q, 8p, 9q, 10p, 10q, 11q,
15q), with an average significance generally lower in schizotypal
traits than schizophrenia, regardless of ethnicity of the sample
and schizotypy measure used (Levinson et al., 2000; Baron, 2001;
DeLisi et al., 2002; Linney et al., 2003; Fanous et al., 2007; Xu
et al., 2009; Lien et al., 2010). However, an Irish study reported
higher significance schizotypal traits compared to patients with
schizophrenia, highlighting chromosomal regions 5q, 9q, and
10p (Fanous et al., 2007). When an analysis was performed using
a combination of both schizophrenia and schizotypy factors in a
population of Taiwan relatives, both negative schizophrenia and
negative schizotypal traits were linked with chromosomal region
10q22.3 while the ones for positive schizophrenia and positive
schizotypy were specific to 5q14.2 and 11q23.3 (Lien et al., 2010).
From the reviewed studies, schizotypal traits do seem to be
expressed at higher levels in relatives of patients with psychotic
disorders compared to the general population. It is less clear
whether patients and their relatives share a vulnerability to
expressing the same subtypes of symptoms, such as common
expression of positive trait/symptomatology. Linkage studies
point to some commonality in symptom expression between
patients and relatives with corresponding chromosomal regions;
however the two family correlational studies did not support this.
The small number of existing linkage studies, suggest the same
chromosomal regions are implicated in both schizotypal traits
and psychotic disorders. Subsequently the candidate genes with
loci within these regions of interest are worthy of investigation in
case-control studies.
SCHIZOTYPAL TRAIT GENES:
ASSOCIATION STUDIES (SCHIZOTYPY,
SCHIZOTYPAL, PSYCHOSIS, PSYCHOTIC,
CANDIDATE GENES, DOPAMINE,
GLUTAMATE, SEROTONIN, GABA, PLUS
SPECIFIC GENES HIGHLIGHTED
THROUGH AN INITIAL LITERATURE
SEARCH)
Several schizophrenia genes have been identified through
systematic fine mapping in regions implicated by linkage analysis
(Liu et al., 2002) and through follow up analysis of linkage
peaks to systematically identify candidate genes (Hennah et al.,
2003; Duan et al., 2004; Petryshen et al., 2005; Pimm et al.,
2005). Due to the small number of linkage studies investigating
schizotypal traits, the candidate genes previously associated with
schizophrenia drive the focus of SNP selection in schizotypal
trait studies. For a disorder such as schizophrenia, which appears
to be genetically complex, genetic markers including SNPs
provide a plausible mechanism to underpin the expression of
attenuated intermediary phenotypes such as schizotypal traits
to be presented within a healthy population. An inherent
assumption in this area is that each genetic marker will confer
a degree of risk for the expression of psychotic disorders, and
it is an accumulation of risk alleles in a dosing manner which
sets background genetic liability. Overall results from literature
search of schizotypy and candidate genes can be found inTable 2.
Among these candidate genes, dystrobrevin-binding protein
1 gene (DTNBP1) located on chromosome 6q22.3 has been
associated with schizophrenia in diverse populations (Bray et al.,
2005; Tochigi et al., 2006; Tosato et al., 2007; Vilella et al.,
2008). This gene codes for a synaptic protein dysbindin 1 which
is found presynaptically. Dysbindin seems to be involved in
the exocytotic glutamate release and cognition processes, in
particular memory (Burdick et al., 2006; Talbot et al., 2006;
Bhardwaj et al., 2009; Hashimoto et al., 2010). SNPs within this
gene are associated with lower levels of dysbindin expression in
post-mortem brain studies (Talbot et al., 2004, 2006), increased
risk for schizophrenia in case-control studies (Straub et al., 2002)
and with paranoid schizotypy in a Caucasian sample (Stefanis
et al., 2008). In reference to glutamatergic functioning, P250
protein is also important given that it plays a significant part
in N-methyl-D-aspartate receptor (NMDAR) mediated spine
development. This protein was found to be highly enriched
in the post-synaptic densities of neurons and is co-localized
with the NR2B subunit of the NMDAR. NDMAR plays an
essential role in the synaptic plasticity and memory performance.
SNPs in the P250 gene have been previously proposed to be
involved in schizophrenia vulnerability (Ohi et al., 2012). In a
Japanese cohort, genetic variant (rs2298599) in the P250 gene
was also found to be significantly associated with high scoring
of schizotypal traits. NRG1 function is mediated by a class of
receptor tyrosine kinases including erbB4 (Li et al., 2007), and
has been shown to associate with schizophrenia (Law et al., 2007)
with altered NRG1/erbB4 signaling being reported in the brains
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TABLE 2 | Summary of SNP studies for schizotypy.
Gene Author Marker Study design N
(% male)
Origin/
Ethnicity
Schizotypy
measure
Association
AHI1 Leach et al., 2013 rs1154801 Cross-sectional
GWAS—healthy
university sample
519 (36%) Caucasian SPQ-BR No significant association
rs2064430 No significant association
AKT1 Leach et al., 2013 rs3803300 Cross-sectional
GWAS—healthy
university sample
519 (36%) Caucasian SPQ-BR No significant association
BDNF Ma et al., 2007 rs6265 Representative healthy
community sample
465 (49%) China SPQ No significant association
C6orf217 Leach et al., 2013 rs10223338 Cross-sectional
GWAS—healthy
university sample
519 (36%) Caucasian SPQ-BR No significant association
CACNA1C Roussos et al.,
2013
rs1006737 Case-controls in
two-wave
GWAS—healthy controls
vs SPD patients
48 HC 50
SPD
Greece STQ
SIDP- IV
Association with paranoid ideation
and (p = 5.0 × 10−4) and unusual
experiences (p = 0.03). The A allele
increased the risk for SPD (p = 0.03,
OR = 1.91) and was associated at a
trend level with paranoia in the SPD
patient group (p = 0.053)
CCKAR Leach et al., 2013 rs1800857 Cross-sectional
GWAS—healthy
university sample
519 (36%) Caucasian SPQ-BR No significant association
CNR1 Arias et al., 2010 rs1049353 Cross-sectional
GWAS—healthy
undergraduates
451 (44%) Spain SPQ-B,
CAPE
No significant association
CNR2 Arias et al., 2010 rs16828926 Cross-sectional
GWAS—healthy
undergraduates
451 (44%) Spain SPQ-B,
CAPE
No significant association
COMT Arias et al., 2010 rs4680 Cross-sectional
GWAS—healthy
undergraduates
451 (44%) Spain SPQ-B,
CAPE
No significant association
Avramopoulos
et al., 2002
rs4680 Cross-sectional
GOI—healthy air force
recruits
379 (100%) Greece SPQ, PAS Those homozygous for high activity
allele had significantly higher scores
on the SPQ (p = 0.024) and the PAS
(p = 0.005)
de Castro-Catala
et al., 2015
rs4680 Cross-sectional GOI 808 (23%) Spain WSS, CAPE Association with higher negative
dimension scores on WSS (p =
0.024) and CAPE (p = 0.004) for
males carrying Val alleles only
Grant et al., 2013 rs4680 Cross-sectional GWAS 288 (31%) Germany O-LIFE Association with full (p = 0.092) and
short (p = 0.031) scale scores for
unusual experiences
Ma et al., 2007 rs4680 Representative healthy
community sample
465 (49%) China SPQ Significant influence on total SPQ (p
= 0.013), disorganization (p =
0.042) and constricted affect (p =
0.027) for males only
rs165599 No significant association
Schürhoff et al.,
2007
rs4680 GOI case-control—first
degree relatives of
probands vs healthy
controls
106 (47%) Caucasian SPQ High activity allele (Val) was
associated with higher cognitive
perceptual (p = 0.001) and
interpersonal deficit (p = 0.04)
scores. Additionally, those
homozygous in Val were associated
with higher total SPQ (p = 0.01)
scores
(Continued)
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TABLE 2 | Continued
Gene Author Marker Study design N
(% male)
Origin/
Ethnicity
Schizotypy
measure
Association
Smyrnis et al.,
2007
rs4680 Cross-sectional
GOI—healthy air force
recruits
1657
(100%)
Greece SPQ, PAS Association with total SPQ (p =
0.03) and negative (p = 0.04),
disorganized (p = 0.02) and
paranoid p = 0.03) factors of the
PAS
Zammit et al.,
2014
rs2097603 Longitudinal general
population representative
GWAS—adolescents
3483 UK PLIKSi Association with definite psychotic
experiences, however no longer
present following correction for
multiple tests
DAAO Stefanis et al.,
2007
rs2111902 Cross-sectional
GWAS—healthy military
conscripts
2076
(100%)
Greece SPQ, PAS,
CAPE
No significant association
rs3918346 No significant association
rs3741775 No significant association
DAOA Leach et al., 2013 rs3916971 Cross-sectional healthy
university sample
519 (36%) Caucasian SPQ-BR No significant association
Stefanis et al.,
2007
rs2391191 Cross-sectional
GWAS—healthy military
conscripts
2076
(100%)
Greece SPQ, PAS,
CAPE
No significant association
rs778293 No significant association
rs3918342 No significant association
DISC1 Leach et al., 2013 rs999710 Cross-sectional healthy
university sample
519 (36%) Caucasian SPQ-BR No significant association
DRD1 Gurvich et al.,
2016
rs778293 Cross-sectional
GOI—healthy individuals
127 Mixed O-LIFE Significant association with negative
dimensions scores (p = 0.010) for
the minor rs4532/C allele
DRD2 Grant et al., 2013 rs1800497 Cross-sectional GWAS 288 (31%) Germany O-LIFE Association of the A1 allele with
impulsive nonconformity scores for
males only
Leach et al., 2013 rs6275 Cross-sectional
GWAS—healthy
university sample
519 (36%) Caucasian SPQ-BR No significant association
rs6277 No significant association
Montag et al.,
2015
rs1800497 Cross-sectional
GWAS—healthy
university sample
471 Caucasian SPQ-B No significant association
Taurisano et al.,
2014
rs1076560 Cross-sectional
GOI—healthy adults
83 Caucasian SPQ Greater total schizotypy scores
associated with minor T allele (p =
0.008)
DRD3 Montag et al.,
2015
rs6280 Cross-sectional
GWAS—university
sample
471 Caucasian SPQ-B No significant association
DTNBP1 Leach et al., 2013 rs1474605 Cross-sectional
GWAS—healthy
university sample
519 (36%) Caucasian SPQ-BR No significant association
rs3213207 No significant association
Stefanis et al.,
2007
rs760761 Cross-sectional
GWAS—Healthy military
conscripts
2076
(100%)
Greece SPQ, PAS,
CAPE
Association with lower scores on the
SPQ dimensions of paranoia (p =
0.007) and cognitive-perceptual
disturbances (p = 0.034) for the
minor allele
rs2619522 Association with lower scores on the
SPQ dimensions of paranoia (p =
0.005), disorganization (p = 0.018)
and cognitive-perceptual
disturbances (p = 0.034) for the
minor allele
(Continued)
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TABLE 2 | Continued
Gene Author Marker Study design N
(% male)
Origin/
Ethnicity
Schizotypy
measure
Association
rs1018381 Association with lower scores on the
SPQ paranoia dimension (p =
0.026), and positive factor of CAPE
(p = 0.043) for the minor allele
rs2619539 No significant association
rs3213207 No significant association
rs1011313 No significant association
rs2005976 No significant association
ERBB4 Stefanis et al.,
2011
rs707284 Cross-sectional
GWAS—healthy military
conscripts
1127
(100%)
Greece SPQ No significant association
rs839523 No significant association
rs7598440 No significant association
Zammit et al.,
2014
rs4673628 Longitudinal general
population representative
GWAS—adolescents
3483 UK PLIKSi Association with definite psychotic
experiences, however no longer
present following correction for
multiple tests
FAAH Arias et al., 2010 rs324420 Cross-sectional
GWAS—healthy
undergraduates
451 (44%) Spain SPQ-B,
CAPE
Interaction between cannabis use
and higher scores on both
SPQ-B-disorganized dimension (p =
0.013) and CAPE- negative
dimension (p = 0.034) for A allele
GABRB2 Leach et al., 2013 rs1816072 Cross-sectional
GWAS—healthy
university sample
519 (36%) Caucasian SPQ-BR No significant association
GNBIL Zammit et al.,
2014
rs2269726 Longitudinal general
population representative
GWAS—adolescents
3483 UK PLIKSi Association with definite psychotic
experiences, however no longer
present following correction for
multiple tests
BRM3 Zammit et al.,
2014
rs6465084 Longitudinal general
population representative
GWAS—adolescents
3483 UK PLIKSi Association with definite psychotic
experiences, however no longer
present following correction for
multiple tests
GWA_11p14.1 Leach et al., 2013 rs1602565 Cross-sectional
GWAS—healthy
university sample
519 (36%) Caucasian SPQ-BR No significant association
GWA_16p13.12Leach et al., 2013 rs7192086 Cross-sectional
GWAS—healthy
university sample
519 (36%) Caucasian SPQ-BR No significant association
HIST1H2BJ Leach et al., 2013 rs6913660 Cross-sectional
GWAS—healthy
university sample
519 (36%) Caucasian SPQ-BR Risk allele carrier greater
cognitive-perceptual scores (p =
0.0134). Became non-significant
after correcting for multiple tests
HTR2A Leach et al., 2013 rs6311 Cross-sectional
GWAS—healthy
university sample
519 (36%) Caucasian SPQ-BR No significant association
MAOA Grant et al., 2013 MAOA-uVNTR Cross-sectional GWAS 288 (31%) Germany O-LIFE Low activity group associated with
greater scores for inattentive
anhedonia for both full (p = 0.016)
and short (p = 0.021) scales, for
males only
MAGI2 Zammit et al.,
2014
rs6951046 Longitudinal general
population representative
GWAS - adolescents
3483 UK PLIKSi Association with definite psychotic
experiences, however no longer
present following correction for
multiple tests
(Continued)
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TABLE 2 | Continued
Gene Author Marker Study design N
(% male)
Origin/
Ethnicity
Schizotypy
measure
Association
MDGA1 Leach et al., 2013 rs11759115 Cross-sectional
GWAS—healthy
university sample
519 (36%) Caucasian SPQ-BR No significant association
rs12191311 No significant association
MIR137 Zammit et al.,
2014
rs1625579 Longitudinal general
population representative
GWAS - adolescents
3483 UK PLIKSi Association with definite psychotic
experiences—risk allele reduced in
frequency
NOTCH4 Leach et al., 2013 rs2071287 Cross-sectional
GWAS—healthy
university sample
519 (36%) Caucasian SPQ-BR No significant association
NRG1 Leach et al., 2013 rs10503929 Cross-sectional
GWAS—healthy
university sample
519 (36%) Caucasian SPQ-BR Risk allele carrier greater
cognitive-perceptual scores (p =
0.0473). Became non-significant
after correcting for multiple tests
Stefanis et al.,
2007
SNP8NRG221132 Cross-sectional GWAS -
healthy military
conscripts
2076
(100%)
Greece SPQ, PAS,
CAPE
No significant association
SNP8NRG221533 No significant association
SNP8NRG241930 No significant association
SNP8NRG243177 No significant association
SNP8NRG433E1006 No significant association
NRGN Leach et al., 2013 rs12807809 Cross-sectional
GWAS—healthy
university sample
519 (36%) Caucasian SPQ-BR No significant association
NRXN1 Zammit et al.,
2014
rs3850333 Longitudinal general
population representative
GWAS - adolescents
3483 UK PLIKSi Association with definite psychotic
experiences, however no longer
present following correction for
multiple tests
NT5C2 Zammit et al.,
2014
rs11191580 Longitudinal general
population representative
GWAS - adolescents
3483 UK PLIKSi Association with definite psychotic
experiences—risk allele reduced in
frequency
PDE4B Leach et al., 2013 rs910694 Cross-sectional
GWAS—healthy
university sample
519 (36%) Caucasian SPQ-BR Risk allele carrier lower total
schizotypy scores (p = 0.0475)
Became non-significant after
correcting for multiple tests
PPP3CC Leach et al., 2013 rs10108011 Cross-sectional
GWAS—healthy
university sample
519 (36%) Caucasian SPQ-BR No significant association
PRODH Ma et al., 2007 rs385440 GOI - representative
healthy community
sample
465 (49%) China SPQ No significant association
rs372055 No significant association
PRSS16 Leach et al., 2013 rs13219354 Cross-sectional
GWAS—healthy
university sample
519 (36%) Caucasian SPQ-BR No significant association
rs6932590 Risk allele carrier greater
cognitive-perceptual scores (p =
0.0363) and greater total schizotypy
scores (p = 0.0266). Becomes
non-significant after correcting for
multiple tests
RELN Leach et al., 2013 rs262355 Cross-sectional
GWAS—healthy
university sample
519 (36%) Caucasian SPQ-BR Risk allele carrier greater
interpersonal (p = 0.0118) and
disorganized scores (p = 0.0401).
Becomes non-significant after
correcting for multiple tests
rs7341475 No significant association
(Continued)
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TABLE 2 | Continued
Gene Author Marker Study design N
(% male)
Origin/
Ethnicity
Schizotypy
measure
Association
RGS4 Leach et al., 2013 rs2661319 Cross-sectional
GWAS—healthy
university sample
519 (36%) Caucasian SPQ-BR Risk allele carrier lower interpersonal
(p = 0.0162), cognitive-perceptual (p
= 0.0125), and total schizotypy
scores (p = 0.0155). Becomes
non-significant after correcting for
multiple tests
Stefanis et al.,
2008
rs2661319 Cross-sectional GWAS -
healthy military
conscripts
1127
(100%)
Greece SPQ Associated with greater SPQ scores
(p = 0.039) for the A allele
rs951436 Association with greater negative
SPQ scores (p = 0.009) for the T
allele
rs951439 No significant association
rs10917670 No significant association
RPP21 Leach et al., 2013 rs3130375 Cross-sectional
GWAS—healthy
university sample
519 (36%) Caucasian SPQ-BR No significant association
SLC6A3 Grant et al., 2013 DAT 3′ UTR-VNTR Cross-sectional GWAS 288 (31%) Germany O-LIFE Cognitive distortion score associated
with 9-repeat-allele in males only
(small sample)
TPH1 Leach et al., 2013 rs1799913 Cross-sectional
GWAS—healthy
university sample
519 (36%) Caucasian SPQ-BR No significant association
ZNF804A Leach et al., 2013 rs1344706 Cross-sectional
GWAS—healthy
university sample
519 (36%) Caucasian SPQ-BR No significant association
Stefanis et al.,
2013
rs7597593 Cross-sectional GWAS -
healthy military
conscripts
1507
(100%)
Greece SPQ, PAS,
CAPE
Significant association with paranoid
SPQ scores (p = 0.004).
Additionally, an association trend
with positive factors for the CAPE
and PAS for individuals with the
major C allele (p =0.081). The A risk
allele was associated with decreased
scores in SPQ factors as well as the
PAS and CAPE positive factor
rs1344706 Significant association with paranoid
(p = 0.02) and disorganization (p =
0.081) SPQ scores. The T risk allele
was associated with decreased
scores in SPQ factors as well as the
PAS and CAPE positive factor
rs4667001 No significant association
rs3731834 No significant association
Yasuda et al.,
2011
rs1344706 Cross-sectional GOI -
healthy individuals
176 (47%) Japan SPQ Association with higher total SPQ
scores (p = 0.042) and
disorganization scores (p = 0.033)
for the risk T allele
SPQ BR, Schizotypal Personality Questionnaire Brief Revised; SPQ, Schizotypal Personality Questionnaire; STQ, Schizotypal Traits Questionnaire; SIDP- IV, Structured Interview for
DSM-IV Personality; CAPE, Community Assessment of Psychic Experiences; SPQ B, Schizotypal Personality Questionnaire Brief version; PAS, Perceptual Aberration Scale; WSS,
Wisconsin Schizotypy Scales; O-LIFE, Oxford-Liverpool Inventory of Feelings and Experiences; PLIKSi, Psychosis-Like Symptoms interview.
of schizophrenia patients (Hahn et al., 2006). Two studies have
investigated SNPs within this gene (Stefanis et al., 2011; Zammit
et al., 2014), and results have been inconsistent with only one SNP
(rs4673628) associating with positive schizotypy.
Genes involved in the regulation of dopamine have been
a strong candidate due to dopamine’s documented role in
schizophrenia and schizotypal traits (e.g., Woodward et al., 2011;
Seeman and Seeman, 2014). Considerable attention has been
given to the catechol-O-methyltransferase gene (or COMT).
This gene codes for an enzyme involved in the breakdown of
catecholamines, including dopamine, at the synapse. A single
variation from G to A at codon 158 of COMT (rs4680) results
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in a valine (Val) to methionine (Met) substitution in the
amino acid sequence of the protein. This change leads to a
functional alteration in the activity of the enzyme: Low (Met),
Medium (Val/Met) and High (Val). Several studies have reported
an association between high activity allele and patients with
schizophrenia (Glatt et al., 2003; Gogos and Gerber, 2006).
Authors suggest that the high activity enzyme leads to lower
dopamine activity in the cortex and can account for both the
negative and cognitive symptoms found in schizophrenia. This
SNP has been associated with higher schizotypy scores in several
gene-wide association studies (GWAS) (Caucasian population:
Avramopoulos et al., 2002; Schürhoff et al., 2007; Smyrnis et al.,
2007; Grant et al., 2013; de Castro-Catala et al., 2015. Chinese
population: Ma et al., 2007) but not all (Caucasian population:
Arias et al., 2010; Grant et al., 2014; Zammit et al., 2014).
A key regulator of the levels of dopamine in the synapses
in brain is the dopamine transporter protein (DAT), encoded
by gene SLC6A3 (located at 5p15.3). Unlike COMT which
operates within the synapse, DAT reuptakes the neurotransmitter
into the presynaptic neuron. Given the functional importance
to neurotransmission of this gene, it has been comparatively
under investigated in relation to schizotypy. The functional
polymorphism of interest is located at the 3′UTR region of
SLC6A3 in a form of a Variable Number Tandem Repeat (VNTR)
of 40 bp. Rare allele 9 carriers of this VNTR were found with
schizotypal features (Grant et al., 2013), however due to the
limited sample this result has to be considered with caution.
Rather than just focusing on the factors involved in breaking
down or taking up neurotransmitters, attention has also been
given to SNPs coding for dopamine receptors. These SNPs can
lead to functional and structural alterations in dopamine (e.g,.
D’Souza and Craig, 2006; Michealraj et al., 2014). Gurvich et al.
(2016) found that dopaminergic receptor D1 was linked to
increased scores on schizotypy factors that resemble negative
symptoms in clinically diagnosable schizophrenia, while Grant
et al. (2014) reported that SNPs in the dopaminergic receptors
D4 and D5 were negatively correlated with schizotypal features.
These authors concluded that schizotypy is associated with
dopamine dysregulation. However, the results for dopamine
receptors as a whole are mixed, with Grant et al. (2013) and
Taurisano et al. (2014) finding an association with schizotypy at
the D2 receptor, which conflicts with the findings of Leach et al.
(2013) and Montag et al. (2015).
Several other functional SNPs with relevance to
neurotransmission and brain maturation have also been
investigated in relation to schizotypy. A factor considered
essential for supporting neuronal growth and promoting
neuronal survival is brain-derived neurotrophic factor (BDNF).
BDNF has been widely investigated for its relevance to
schizophrenia (Kheirollahi et al., 2016). Proline is an amino
acid which is found in excess in patients with schizophrenia.
There is a SNP of interest in the gene coding for proline
oxidase enzyme, which is able to metabolize (PRODH).
Additionally, a SNP coding for D-Amino Acid Oxidase enzyme
involved in glutamatergic neurotransmission (DAAO), has
been demonstrated to be associated with schizophrenia in case-
control studies (Caldinelli et al., 2013). One study in a Chinese
population (Yang et al., 2013), found no association between
these SNPs and schizotypy scores. Similarly, after correction for
multiple comparisons, no significant associations were observed
between SNPs in DAAO gene and schizotypy in a Greek military
healthy cohort (Stefanis et al., 2007). The same cohort was
employed to evaluate risk factors for schizotypy for selected
SNPs in RGS4 gene. The RGS4 gene codes for Regulator of G
protein signaling, which is involved in intracellular signaling in
glutamatergic and dopaminergic receptors. Genetic variant for
rs951436 and rs2661319 were associated with negative schizotypy
and total schizotypy respectively, however none of the tested
SNPs were associated with cognitive indices, despite the seeming
functional importance of RGS4 (Stefanis et al., 2008).
Looking at other candidate neuronal receptors, genetic
variants for CACNA1C gene has been of interest to some
investigators. This gene codes for a sub-unit of the calcium
channel which regulates the calcium influx into the cells; a
mechanism which has implications for learning and memory.
One SNP in this gene (rs1006737) has been previously associated
with schizophrenia (Porcelli et al., 2015). In a Caucasian sample,
schizotypal paranoid ideation was associated with this SNP
(Roussos et al., 2011). In another study from the same group,
the same genetic variant was positively associated with interview
assessed schizotypal personality disorder paranoid ideation and
unusual experiences (Roussos et al., 2013). Given the replication
of an association between schizotypal traits and this SNP it is
worthy of investigation in future studies.
An increasing area of exploration in association studies is
the zinc finger (ZNF) family. The ZNF family plays roles in
the binding of DNA- and RNA proteins; where amino acids
are folded into a single structural unit around a zinc atom
to stabilize the fold (Sun et al., 2015). They are involved in
multiple functions, including transcriptional activation, protein
folding, RNA packaging, lipid binding, and DNA recognition
(Laity et al., 2001). Recently, focus has been given to specific SNPs
of ZNF804A (e.g., rs1344706, rs4667001, and rs728534) with a
meta-analysis by Zhu et al. (2014) showing an association with
schizophrenia risk in both Asian and Caucasian populations.
When investigating these SNPs in reference to schizotypy, we see
mixed results with some studies finding a significant association
with schizotypy (Yasuda et al., 2011; Stefanis et al., 2013) and
others not (Leach et al., 2013).
There is burgeoning interest in whether genes inherited from
the maternal and paternal lines have differing effects, known as
imprinting. This has been partly driven by consistent findings
for increasing paternal age being related to psychosis risk (Foutz
and Mezuk, 2015; Martin et al., 2015) and speculation on what
mechanism may be underpinning this. Additionally, the role
of imprinting in psychiatric genetics is becoming more widely
speculated upon and a point for consideration within psychotic
disorders (Crespi, 2008). In support of this the imprinted
gene LRRTM1 (Leucine-rich repeat transmembrane neuronal
1) was reported to be a risk factor for mental illness such as
schizophrenia when the gene was inherited from the father
(Francks et al., 2007). LRRTM1 plays a significant role in brain
development and reflects a variable profile of maternal regulation
(Francks et al., 2007). Given that schizophrenia and schizotypal
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traits are considered to be neurodevelopmental, this gene may
be of functional significance. Three SNPs (rs1007371, rs1446109,
rs723524) in the LRRTM1 gene were examined in a student
Canadian cohort for their association with a brief measure of
schizotypy (Leach et al., 2014). However, none of the tested SNPs
were significantly associated with schizotypy after correction
for multiple comparisons. Given the gene’s significance for
neurodevelopment and maturation of the brain, potentially
through the lifespan, this requires further investigation.
To some extent linkage studies have led to SNPs previously
associated with schizophrenia being investigated for their
relevance to schizotypal traits. The findings from the SNP studies
are mixed, at best. However, they are similarly mixed using
patient groups, where a concentrated expression of biological
risk is found. The advantage of examining schizotypy in healthy
populations is the potential to achieve large sample sizes, often
compromised in patient case-control studies. However, there
are caveats to such an approach. First the genetic risk will be
“watered-down” in the attenuated schizotypal traits. Assuming
a polygenic approach to risk, this will mean each individual
will carry fewer at risk alleles. Secondly, there is as much
heterogeneity in the expression of schizotypal traits in the healthy
population as there is in the presentation of symptoms in patient
populations. Thirdly, it is possible that schizotypes also carry
protective SNPs which decrease the likelihood of transition to
psychosis, this complicates a scenario which we know represents
the convergence of multifaceted riskmarkers, only some of which
are biological in nature. To date, few studies have taken advantage
of the possibility of using large sample sizes to investigate
the genetic underpinnings of schizotypy. There may be both
pragmatic and theoretical concerns at play. Some still appear
to question the utility of schizotypy to investigate psychotic
disorders, questioning its role in risk for psychosis as well as the
possibility it represents a useful intermediate phenotype. Others
question the degree to which it is of interest in itself. These
continued concerns being voiced in the literature ensure that
obtaining funding to investigate the biological underpinnings of
schizotypy can be difficult; restricting the investigation of the
genetic underpinnings to often already established population
databases where measures are limited and phenotypic refinement
not possible. Finally, there are sample overlaps in the studies
summarized here. Multiple research groups need to investigate
these questions, each with their own approach to ensure that
thorough and representative research eventuates in the future.
GENETIC DISORDERS REPORTING
SCHIZOTYPAL TRAITS (SCHIZOTYPY,
SCHIZOTYPAL, PSYCHOSIS, PSYCHOTIC,
SCHIZOPHRENIA, GENETIC DISORDERS,
DEVELOPMENTAL DISORDERS)
Alongside the traditional methods of linkage, family studies
and SNPs examining the underpinnings of the psychosis
continuum, an alternative approach exists. There are a number
of genetic disorders, with well-characterized genetic deletions
or insertions, where rates of schizophrenia are considered to
be higher than those found in the general population. In
these instances, the genetic mutations are established, often
with documented physical and psychological implications. It
is possible that consideration of these disorders in relation to
schizotypal traits would assist in providing additional evidence
for the biological mechanisms underpinning the expression of
these traits. Interestingly, given the current diagnostic manuals,
individuals with well-defined genetic variations cannot receive
a diagnosis of schizophrenia. However, some debate surrounds
whether psychotic symptom presentation in those with genetic
variations differs from the strict definition of schizophrenia (e.g.,
Bassett et al., 2003). A brief overview of genetic disorders with
elevated rates of schizophrenia, where consideration has been
given to schizotypal traits will be outlined.
Perhaps the most well-known genetic disorder associated with
psychotic disorders is Chromosome 22q11.2 deletion syndrome.
Deletion of 22q11.2 underpins a group of syndromes including
DiGeorge syndrome, velocardiofacial syndrome (VCFS; also
called Shprintzen syndrome), Opitz G/BBB syndrome and
Conotruncal anomaly face syndrome. Chromosome 22q11.2
deletion syndrome is associated with physical problems in the
cleft palate, heart, kidneys, lungs, autoimmune problems, and
distinctive facial features. Many individuals have lower IQ than
the general population, are developmentally delayed and have
cognitive deficits. The deletion occurs in 1:5000 live births
(Botto et al., 2003); although some argue rates may be much
higher, given the heterogeneity of presentation it is possible
those with the deletion will receive an alternative diagnosis and
may not receive genetic testing. There is substantial evidence
documenting elevated rates of schizophrenia in adolescence
and adulthood in those with 22q11.2 deletion syndrome when
compared to the general population. In addition, they appear
to be at greater risk for developing schizophrenia than other
learning disabled individuals (Gothelf et al., 2007). The existence
of subclinical psychotic symptoms in children and adolescents
with 22q11.2 deletion syndrome has clinical predictive validity
for future psychotic disorders (Gothelf et al., 2007). Indeed,
Debbané et al. (2006) reported 28% of their child and adolescent
sample had psychotic symptoms. Consequently, the examination
of schizotypal features in 22q11.2 deletion syndrome individuals
is clinically valid as a potential preventative measure in this
group as well as providing additional information concerning the
pathogenesis of the psychosis.
Monks et al. (2014) reported rates of schizotypy to be
higher in a 22q11.2 deletion sample compared to controls,
even when participants with a current psychotic disorder were
excluded from the 22q11.2 deletion group. Adolescents with
22q11.2 deletion syndrome have been reported to have elevated
interpersonal schizotypal traits compared to controls, and the
assessment of these traits appeared to be consistent over a
three year period (Fonseca-Pedrero et al., 2016). In addition,
higher levels of negative schizotypal traits have been reported
in those with 22q11.2 deletion when compared to controls,
even after controlling for anxiety, depression and full scale
intelligence (Schneider et al., 2015). There are a number of
genes captured by the 22q11.2 deletion area, these include:
COMT, PRODH, zinc finger gene (ZDHHC8) and armadillo
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repeat protein deleted in velocardiofacial syndrome (ARVCF;
see Harrison and Weinberger, 2005; Prasad et al., 2008 for
reviews). Polymorphisms in these genes have been varyingly
associated with cognitive deficits, schizophrenia, high schizotypy
and psychotic symptoms both in psychiatric populations and
in 22q11.2 samples. However, these associations have not been
consistently reported; and, to date, it is difficult to determine
whether negative findings are due to sample differences
(e.g., cultural variation in allelic frequency), sex differences,
phenotypic heterogeneity or low statistical power.
A disorder which has also been investigated for its similarities
to schizophrenia is that of Fragile X syndrome (for example
see Kelemen et al., 2013). In Fragile X there is a mutation
of multiple CGG repeats on the X chromosome located in an
area coding for a protein which appears to be fundamental
to healthy brain development and functioning. The phenotypic
characteristics of the disorder are developmental delays and
cognitive impairments. Additionally, carriers (particularly males)
can express psychomotor and cognitive difficulties as they age.
Although in children Fragile X is most closely associated with
autism spectrum and other pervasive developmental disorders
(e.g., Franke et al., 1996; Tsiouris and Brown, 2004), some studies
have suggested there may be a link with psychotic disorders.
Given the overlapping pathophysiology of dysregulation in
BDNF, glutamate and gamma-Aminobutyric acid (GABA)
shared by Fragile X and schizophrenia, the potential for common
causal pathways seems plausible. A number of studies have also
reported associations between elevated rates of schizotypal traits
and Fragile X chromosomal abnormalities (Reiss et al., 1988;
Kerby and Dawson, 1994; Sobesky et al., 1994; Franke et al.,
1996). However, given the levels of social anxiety and withdrawal
in those with Fragile X syndrome it would be worthwhile further
investigating which aspects of schizotypy are elevated in this
syndrome. The overlapping pathophysiology with schizophrenia
certainly makes the area of the chromosome affected in Fragile
X of significance for those concerned schizophrenia etiology.
However, phenotypic presentation, particularly in males, is
more developmentally pervasive than the later presentation of
symptoms in psychotic disorders. Researchers have linked the
expression of Fragile X protein to symptoms and age of onset
of schizophrenia (Hossein and Folsom, 2011; Kovács et al.,
2013). Therefore, Fragile X protein levels deserve consideration
in schizotypal individuals.
Another sex chromosome linked disorder of interest is
Klinefelter syndrome where individuals have a 47 XXY
karyotype, possessing an extra X chromosome. It occurs in
approximately 1 in 670 male births (Bojesen et al., 2003). Many
of the genes on the additional X chromosome are inactive which
accounts for the relatively mild presentation of difficulties in
Klinefelter’s compared to other genetic disorders. However, there
are some genes on the X chromosome which are homologous
with those found on the Y chromosome and consequently are
expressed. Males with Klinefelter’s tend to be tall in stature,
experience difficulties in hormonal expression, experience
gynecomastia and infertility. Cognitive deficits in verbal domains
(including dyslexia) are most commonly reported (e.g., Fales
et al., 2003). The brain structural abnormalities found in
Klinefelter’s individuals are similar to those reported in patients
with schizophrenia, including temporal lobe abnormalities,
enlarged ventricles and structurally and functionally reduced or
reversed asymmetries (e.g., Reiss et al., 2000; Itti et al., 2003;
DeLisi et al., 2005). Approximately, 0.8–1% of male inpatients
with schizophrenia are found to have an XXY karyotype (DeLisi
et al., 1994). Rates of psychotic symptoms (DeLisi et al., 1994) and
psychotic disorders (Bojesen et al., 2006; Cederlöf et al., 2014)
are elevated in Klinefelter’s individuals compared to the general
population (although seeMors et al., 2001). Studies have reported
that schizotypal traits are higher in those with Klinefelter’s
when compared to healthy controls (Van Rijn et al., 2006, 2009;
Verhoeven and Egger, 2011). Some authors have suggested that
the association between Klinefelter’s and schizotypal traits is
a function of the cognitive disorganization and verbal deficits
found in the genetic syndrome. However, those with Klinefelter’s
also have elevated diagnoses of autism spectrum, ADHD and
bipolar disorders; consequently, the higher schizotypal scores
could be an expression of vulnerability to psychopathology in
general rather than a demonstrated specificity for psychotic
disorders.
Genetic disorders in some ways allow for the possibility
of minimizing heterogeneity of genetic abnormalities within
a well characterized subpopulation to enable exploration of
the consequent phenotypic presentations. However, as yet it
is poorly understood how the general genetic background
would act to mediate or moderate deletions and insertions.
Therefore, the possibility of the effects of epistatic interactions
shaping phenotypic expression of genetic disorders needs to be
more fully explored. One commonality in presentation of the
genetic disorders highlighted above is cognitive deficits. It would
be tempting to conclude that the associations with psychotic
disorders and schizotypal traits are through a common causal
pathway relating to cognitive vulnerabilities in verbal abilities
and executive function. However, other developmental disorders
such as Downs Syndrome also display cognitive deficits and yet
do not have an over representation of psychotic disorders; thus a
seemingly simple hypothesis is unsupported given that it cannot
be generalized. Further work is needed to determine which
aspects of the genetic disorders are particularly predictive of
schizotypal traits and whether cognitive deficits, social difficulties
or common biological pathways are the crucial factors in
determining risk for schizotypal traits.
CONCLUSIONS AND FUTURE
DIRECTIONS
The selection of genetic variations investigated for their
association with schizotypal traits has been largely shaped
by studies concerned with schizophrenia. These include
microsatellite, SNPs, insertions and deletions in neurobiological
pathways known to be aberrant in psychotic disorders, including
dopamine, glutamate and GABA. The authors were surprised
by the relative paucity of papers which considered the genetic
underpinnings of schizotypal traits. Unlike the clinical end
point of psychotic disorders, schizotypal traits can be readily,
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cheaply and efficiently characterized using well validated and
established measures (Mason, 2015). In contrast to psychotic
symptoms, schizotypal traits are stable by virtue of the fact
they are defined as a personality construct. Whilst some aspects
of the behaviors comprising schizotypal traits may fluctuate,
such as the presentation of isolated psychotic symptoms, the
core of schizotypal traits will be consistently detectable over
multiple time points. Schizotypal traits have been found to
be associated with similar environmental factors, such as
urbanicity, to those reported for elevating risk for psychotic
disorder (e.g., Nelson et al., 2013). Collectively these factors
shape a strong argument for considering schizotypal traits as
being related to schizophrenia. Many of the studies included
in this review have considered schizotypal traits as a whole
(although see Mata et al., 2000, 2003). We have referred to
schizotypal traits as plural because they comprise a number of
behaviors and psychological phenomena. In addition, theorists
in this area emphasize either the individual difference or
clinical relevance of these traits. These considerations lead
to differences in the measures used and whether differing
dimensions (positive, negative, unusual experiences, cognitive
disorganization, interpersonal) are emphasized. It is possible
that these differences in measurement account for some of the
inconsistencies in genetic association studies. Indeed, some
of the dimensions of schizotypal traits could be more likely
to be underpinned by stable genetic factors. For instance,
disorganization and interpersonal schizotypal traits have a
stability to them which suggests biological underpinnings are
more plausible. Whilst a propensity toward unusual perceptual
experiences may be further “down stream” of genetic influences,
given that they are likely triggered by factors such as stress
or substance use. Linkage studies have not as yet provided
evidence for the genomic components which confer risk for
schizotypal traits within families. A gene-dosing relationship
is implied between psychotic disorders and schizotypal traits,
given that there are elevated levels in relatives of patients with
schizophrenia compared to the general population. This suggests
further investigation of the biological correlates of schizotypal
traits is warranted.
However, whether these investigations should be exclusively
guided by the pathophysiology of schizophrenia could be a
matter of debate. Given the assumption that schizotypal traits
exist on a continuum with psychotic disorders, it seems likely
that at least some of the genetic liability for schizophrenia
should underpin schizotypal traits; yet, this is fraught with
difficulties. Schizotypal individuals will likely possess some of
the genetic liability for psychotic disorders but also some
biological protective factors which assist in preventing transition
to a diagnosable psychotic disorder. Although we recognize
that risk for psychotic disorders is an interaction between
genetic and environmental factors, existing evidence points
to a strong role for genetic and biological vulnerability.
In addition, it is possible that schizotypal traits present a
broad phenotype for the liability to serious mental health
disorders in general rather than psychotic disorders per se.
The evidence accumulated here from genetic disorders may
provide intriguing evidence for this. Schizotypal traits may
be elevated in genetic disorders which over express psychotic
disorders, however, these same genetic disorders also over
represent pervasive developmental disorders, ADHD and bipolar
disorder.
The authors could not find any papers which examined the
interaction between genes and the environment for schizotypal
traits. From a theoretical perspective this may be due to the
assumed stability in a personality trait. A longitudinal study
could track the effects of childhood events on the differing
trajectories theorized to occur with schizotypal traits in response
to environmental factors (Raine, 2006). Alternatively, shorter
longitudinal follow up periods could reveal environmental
factors in adulthood which exacerbate the presentation of
schizotypal traits. These studies could consider the effects of
particular genetic variations highlighted in this review. Such a
design also has the potential to identify protective as well as risk
genes. The investigation of gene-environment interactions on
schizotypal traits is certainly an area for development. There are
a number of papers considering gene-environment interactions
for psychotic symptoms (e.g., Alemany et al., 2011; Ramsay
et al., 2013). This perhaps suggests a way forward may be to
refine the measurement of the schizotypal phenotype with the
addition of state-like measures capturing psychotic symptoms
separately. In this way gene-environment interactions could
investigate effects along the psychosis continuum for expression
of psychotic symptoms against a background risk of schizotypal
traits. Whilst theoretically robust this is statistically complex
and would require a relatively large sample size in order
to have sufficient power to detect what, will likely be small
effects.
The genetic disorders reviewed highlight the potential role for
cognitive deficits being an additional factor for psychosis risk.
From the perspective of investigation of genetic underpinnings,
cognitive performance has many appealing features. It is
objectively definable on the basis of performance rather than
self-report; and, it is closer to the expression of genes than
collections of (personality) behaviors, given that it can be linked
to particular brain areas. Cognitive performance has been linked
more consistently to genetic variation (e.g., Park and Waldman,
2014; Heck et al., 2014). Cognitive deficits can be linked to the
structural brain abnormalities reported in genetic disorders. This
provides a link from well characterized genetic polymorphisms
to changes in brain structure which could underpin the cognitive
deficits found in genetic disorders. Brain structure abnormalities
have been found in those with schizotypal traits who are
otherwise healthy individuals (e.g., Smallman et al., 2014).
Therefore, in those characterized for both their schizotypal and
genetic profiles, we could examination associations between
carefully selected genetic polymorphisms, gray and white matter
density and cognitive performance. In this way, research can
begin to close the gap between the neurodevelopmental effects
of the gene, their cognitive outcomes and whether these differ
with schizotypal traits. Cognitive deficits are found across a
number of genetic and mental health disorders; consequently,
they do not represent an alternative single end point for
genetic studies. Rather they offer a way to refine a complex
and heterogeneous phenotype like schizotypy. For instance,
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schizotypes who have poorer cognitive performance could
represent a subtype that may be genetically enriched for risk.
Distinguishing their genetic profile from schizotypes with intact
cognitive performance could, therefore, begin to tease out the
complexities of psychosis liability where we see multiple factors
converging.
The genetic underpinnings of schizotypal traits have received
limited attention; there has been substantial focus on general
psychosis risk rather than an emphasis on schizotypal traits
specifically. As such there is the opportunity for further
investigation and exploration. Using the investigations of
psychotic disorders represents a start point for identification of
genes of interest for schizotypal traits but focus needs to be
widened. Investigations now are examining the genes associated
with particular symptoms with minimal attention to diagnostic
category (e.g., Craddock et al., 2009; Hamshere et al., 2009). This
broader scope represents a way forward for the investigation
of schizotypal traits. As such, perhaps we need to consider the
genetic underpinnings of the differing dimensions of schizotypal
traits rather than focusing on the intermediate phenotype
as a whole. Given that schizotypy is heterogeneous, more
refinement of the clinical end point of interest needs considering;
the inclusion of a cognitive or psychotic symptom measure
could help to narrow the specificity for genetic association
studies.
AUTHOR CONTRIBUTIONS
EW Contribution to the conception and design of the review,
literature search for acquisition of studies, drafting of section 2.1
and 3 of the manuscript, critical review, editing, and formatting
of the full manuscript and final approval of the version to be
submitted. FF Contribution to the conception and design of the
review, literature search for section 2.2, drafting of section 2.2,
and 3, Critical review of manuscript and final approval of the
version to be submitted. MS Contribution to the conception and
design of the review, literature search for acquisition of studies for
inclusion in the review, drafting of section 3, and final approval of
the version to be submitted. EB Contribution to the conception
and design of the review, literature search for acquisition of
studies, drafting of sections 1, 4, and 5. Critical review of sections
2.1, 2.2, and 3. Editorial review of full manuscript and final
approval of the version to be submitted. All authors agree to be
accountable for all aspects of the work
FUNDING
EB is funded by the NARSAD Young Investigator Award, in kind
support from GW Pharmaceuticals, and two internal grants for
the University of Wollongong FF is funded by an NHMRC grant.
REFERENCES
American Psychiatric Association. (2013). Diagnostic and Statistical Manual of
Mental Disorders (5th ed.). Washington, DC: American Psychiatric Association.
Alemany, S., Arias, B., Aguilera, M., Villa, H., Moya, J., Ibáñez, M. I., et al. (2011).
Childhood abuse, the BDNF-Val66Met polymorphism and adult psychotic-like
experiences. Br. J. Psychiat. 199, 38–42. doi: 10.1192/bjp.bp.110.083808
Appels, M. C., Sitskoorn, M. M., Vollema, M. G., and Kahn, R. S. (2004).
Elevated levels of schizotypal features in parents of patients with a family
history of schizophrenia spectrum disorders. Schizophr. Bull. 30, 781–790. doi:
10.1093/oxfordjournals.schbul.a007131
Arias, B., Fatjo-Vilas, M., Estrada, G., Aguilera, Mc., Mitjans, M., Moya, J.
et al. (2010). The analysis of genetic variability at COMT, CNR1, CNR2 and
FAAH genes on cannabis use, schizotypy and psychotic-like experiences: a
study in a Spanish general population. Schizophr. Res. 117, 307–308. doi:
10.1016/j.schres.2010.02.515
Avramopoulos, D., Stefanis, N. C., Hantoumi, I., Smyrnis, N., Evdokimidis, I.,
and Stefanis, C. N. (2002). Higher scores of self reported schizotypy in healthy
youngmales carrying the COMThigh activity allele.Mol. Psychiatry 7, 706–711.
doi: 10.1038/sj.mp.4001070
Baron, M. (2001). Genetics of schizophrenia and the new millennium: progress
and pitfalls. Am. J. Hum. Genet. 68, 299–312. doi: 10.1086/318212
Bassett, A. S., Chow, E., AbdelMalik, P., Gheorghiu, M., Husted, J., and Weksberg,
R. (2003). The schizophrenia phenotype in 22Q deletion syndrome. Schizophr.
Res. 60, 78. doi: 10.1016/S0920-9964(03)80618-7
Bergman, A. J., Silverman, J. M., Harvey, P. D., Smith, C. J., and Siever, L. J.
(2000). Schizotypal symptoms in the relatives of schizophrenia patients: an
empirical analysis of the factor structure. Schizophr. Bull. 26, 577–586. doi:
10.1093/oxfordjournals.schbul.a033479
Bhardwaj, S. K., Baharnoori, M., Sharif-Askari, B., Kamath, A., Williams, S., and
Srivastava, L. K. (2009). Behavioral characterization of dysbindin-1 deficient
sandy mice. Behav. Brain Res. 197, 435–441. doi: 10.1016/j.bbr.2008.10.011
Bojesen, A., Juul, S., Birkebæk, N. H., and Gravholt, C. H. (2006). Morbidity
in Klinefelter syndrome: a Danish register study based on hospital discharge
diagnoses. J. Clin. Endocrinol. Metab. 91, 1254–1260. doi: 10.1210/jc.2005-0697
Bojesen, A., Juul, S., and Gravholt, C. H. (2003). Prenatal and postnatal prevalence
of Klinefelter syndrome: a national registry study. J. Clin. Endocrinol. Metab.
88, 622–626. doi: 10.1210/jc.2002-021491
Botto, L. D., May, K., Fernhoff, P. M., Correa, A., Coleman, K., Rasmussen, S.
A., et al. (2003). A population-based study of the 22q11.2 deletion: phenotype,
incidence, and contribution to major birth defects in the population. Pediatrics
112, 101–107. doi: 10.1542/peds.112.1.101
Brambilla, P., Fagnani, C., Cecchetto, F., Medda, E., Bellani, M., Salemi,
M., et al. (2014). Genetic and environmental bases of the interplay
between magical ideation and personality. Psychiatry Res. 215, 453–459. doi:
10.1016/j.psychres.2013.11.021
Bray, N. J., Preece, A., Williams, N. M., Moskvina, V., Buckland, P. R., Owen, M. J.,
et al. (2005). Haplotypes at the dystrobrevin binding protein 1 (DTNBP1) gene
locus mediate risk for schizophrenia through reduced DTNBP1 expression.
Hum. Mol. Genet. 14, 1947–1954. doi: 10.1093/hmg/ddi199
Burdick, K. E., Lencz, T., Funke, B., Finn, C. T., Szeszko, P. R., Kane, J. M., et al.
(2006). Genetic variation in DTNBP1 influences general cognitive ability.Hum.
Mol. Genet. 15, 1563–1568. doi: 10.1093/hmg/ddi481
Caldinelli, L., Sacchi, S., Molla, G., Nardini, M., and Pollegioni, L. (2013).
Characterization of human DAAO variants potentially related to an
increased risk of schizophrenia. Biochim. Biophys. Acta 1832, 400–410. doi:
10.1016/j.bbadis.2012.11.019
Cardno, A. G., Marshall, E. J., Coid, B., Macdonald, A. M., Ribchester, T. R.,
Davies, N. J. et al. (1999). Heritability estimates for psychotic disorders:
the maudsley twin psychosis study. Arch. Gen. Psychiatry 56, 162–168. doi:
10.1001/archpsyc.56.2.162
Cederlöf, M., Ohlsson Gotby, A., Larsson, H., Serlachius, E., Boman, M.,
Långström, N., et al. (2014). Klinefelter syndrome and risk of psychosis, autism
and ADHD. J. Psychiatr. Res. 48, 128–130. doi: 10.1016/j.jpsychires.2013.10.001
Chang, C.-J., Chen, W. J., Liu, S. K., Cheng, J. J., Yang, W.-C. O., Chang, H.-J.,
et al. (2002). Morbidity risk of psychiatric disorders among the first degree
relatives of schizophrenia patients in Taiwan. Schizophr. Bull. 28, 379–392. doi:
10.1093/oxfordjournals.schbul.a006947
Claridge, G., andHewitt, J. K. (1987). A biometrical study of schizotypy in a normal
population. Pers. Individ. Dif. 8, 303–312. doi: 10.1016/0191-8869(87)90030-4
Frontiers in Psychology | www.frontiersin.org 15 November 2016 | Volume 7 | Article 1769
Walter et al. Genetics and Schizotypy Review
Clementz, B. A., Grove, W. M., Katsanis, J., and Iacono, W. G. (1991).
Psychometric detection of schizotypy: perceptual aberration and physical
anhedonia in relatives of schizophrenics. J. Abnorm. Psychol. 100, 607–612. doi:
10.1037/0021-843X.100.4.607
Craddock, N., O’Donovan, M. C., and Owen, M. J. (2009). Psychosis genetics:
Modeling the relationship between schizophrenia, bipolar disorder and
mixed (or “schizoaffective”) psychoses. Schizophr. Bull. 35, 482–490. doi:
10.1093/schbul/sbp020
Crespi, B. (2008). Genomic imprinting in the development and evolution of
psychotic spectrum conditions. Biol. Rev. 83, 441–493. doi: 10.1111/j.1469-
185x.2008.00050.x
D’Souza, U. M., and Craig, I. W. (2006). Functional polymorphisms in dopamine
and serotonin pathway genes. Hum. Mutat. 27, 1–13. doi: 10.1002/humu
Debbané, M., Glaser, B., David, M. K., Feinstein, C., and Eliez, S. (2006). Psychotic
symptoms in children and adolescents with 22q11.2 deletion syndrome:
Neuropsychological and behavioral implications. Schizophr. Res. 84, 187–193.
doi: 10.1016/j.schres.2006.01.019
de Castro-Catala, M., Barrantes-Vidal, N., Sheinbaum, T., Moreno-Fortuny, A.,
Kwapil, T. R., and Rosa, A. (2015). COMT-by sex interaction effect on psychosis
proneness. J. Biomed. Biotechnol. 2015:829237. doi: 10.1155/2015/829237
DeLisi, L. E., Friedrich, U., Wahlstrom, J., Boccio-Smith, A., Forsman, A., Eklund,
K., et al. (1994). Schizophrenia and sex chromosome anomalies. Schizophr. Bull.
20, 495–505. doi: 10.1093/schbul/20.3.495
DeLisi, L. E., Maurizio, A. M., Svetina, C., Ardekani, B., Szulc, K., Nierenberg, J.,
et al. (2005). Klinefelter’s syndrome (XXY) as a genetic model for psychotic
disorders. Am. J. Med. Genet. 135, 15–23. doi: 10.1002/ajmg.b.30163
DeLisi, L. E., Shaw, S. H., Crow, T. J., Shields, G., Smith, A. B., Larach, V. W.,
et al. (2002). A genome-wide scan for linkage to chromosomal regions in 382
sibling pairs with schizophrenia or schizoaffective disorder. Am. J. Psychiatry
159, 803–812. doi: 10.1176/appi.ajp.159.5.803
Duan, J., Martinez, M., Sanders, A. R., Hou, C., Saitou, N., Kitano, T., et al. (2004).
Polymorphisms in the trace amine receptor 4 (TRAR4) gene on chromosome
6q23.2 are associated with susceptibility to schizophrenia. Am. J. Hum. Gen. 75,
624–638. doi: 10.1086/424887
Fales, C. L., Knowlton, B. J., Holyoak, K. J., Geschwind, D. H., Swerdloff,
R. S., and Gonzalo, I. G. (2003). Working memory and relational
reasoning in Klinefelter syndrome. J. Int. Neuropsychol. Soc. 9, 839–846. doi:
10.1017/s1355617703960036
Fanous, A. H., Neale, M. C., Gardner, C. O., Webb, B. T., Straub, R. E., O’Neill,
F., et al. (2007). Significant correlation in linkage signals from genome-wide
scans of schizophrenia and schizotypy. Mol. Psychiatry 12, 958–965. doi:
10.1038/sj.mp.4001996
Fogelson, D. L., Nuechterlein, K. H., Asarnow, R. F., Payne, D. L., Subotnik, K.
L., and Giannini, C. A. (1999). The factor structure of schizophrenia spectrum
personality disorders: signs and symptoms in relatives of psychotic patients
from the UCLA family members study. Psychiatry Res. 87, 137–146. doi:
10.1016/S0165-1781(99)00086-4
Fonseca-Pedrero, E., Debbané, M., Schneider, M., Badoud, D., and Eliez, S.
(2016). Schizotypal traits in adolescents with 22q11.2 deletion syndrome:
validity, reliability and risk for psychosis. Psychol. Med. 46, 1005–1013. doi:
10.1017/S0033291715002500
Foutz, J., and Mezuk, B. (2015). Advanced paternal age and risk of psychotic-
like symptoms in adult offspring. Schizophr. Res. 165, 123–127. doi:
10.1016/j.schres.2015.04.014
Francks, C., Maegawa, S., Laurén, J., Abrahams, B. S., Velayos-Baeza, A., Medland,
S. E., et al. (2007). LRRTM1 on chromosome 2p12 is a maternally suppressed
gene that is associated paternally with handedness and schizophrenia. Mol.
Psychiatry 12, 1129–1057. doi: 10.1038/sj.mp.4002053
Franke, P., Maier, W., Hautzinger, M., Weiffenbach, O., Gänsicke, M.,
Iwers, B., et al. (1996). Fragile-X carrier females: evidence for a distinct
psychopathological phenotype? Am. J. Med. Genet. 64, 334–339.
Fusar-Poli, P., Bechdolf, A., Taylor, M. J., Bonoldi, I., Carpenter, W. T., Yung, A. R.,
et al. (2013). At risk for schizophrenic or affective psychoses? A meta-analysis
of DSM/ICD diagnostic outcomes in individuals at high clinical risk. Schizophr.
Bull. 39, 923–932. doi: 10.1093/schbul/sbs060
Glatt, S. J., Faraone, S. V., and Tsuang, M. T. (2003). Association between
a functional catechol O-methyltransferase gene polymorphism and
schizophrenia: meta-analysis of case-control and family-based studies.
Am. J. Psychiatry 160, 469–476. doi: 10.1176/appi.ajp.160.3.469
Gogos, J. A., and Gerber, D. J. (2006). Schizophrenia susceptibility genes:
emergence of positional candidates and future directions. Trends Pharmacol.
Sci. 27, 226–233. doi: 10.1016/j.tips.2006.02.005
Gothelf, D., Feinstein, C., Thompson, T., Gu, E., Penniman, L., Van Stone,
E., et al. (2007). Risk factors for the emergence of psychotic disorders in
adolescents with 22q11.2 deletion syndrome. Am. J. Psychiatry 164, 663–669.
doi: 10.1176/ajp.2007.164.4.663
Grant, P., Gabriel, F., Kuepper, Y., Wielpuetz, C., and Hennig, J. (2014). Psychosis-
proneness correlates with expression levels of dopaminergic genes. Eur.
Psychiatry 29, 304–306. doi: 10.1016/j.eurpsy.2013.12.002
Grant, P., Kuepper, Y., Mueller, E. A., Wielpuetz, C., Mason, O. J.,
and Hennig, J. (2013). Dopaminergic foundations of schizotypy as
measured by the German version of the Oxford-Liverpool Inventory
of Feelings and Experiences (O-LIFE)-a suitable endophenotype of
schizophrenia. Front. Hum. Neurosci. 7:1. doi: 10.3389/fnhum.2013.
00001
Grove, W. M., Lebow, B. S., Clementz, B. A., Cerri, A., Medus, C., and Iacono,
W. G. (1991). Familial prevalence and coaggregation of schizotypy indicators:
a multitrait family study. J. Abnorm. Psychol. 100, 115–121. doi: 10.1037/0021-
843X.100.2.115
Gurvich, C., Bozaoglu, K., Neill, E., Van Rheenen, T. E., Tan, E. J., Louise, S.,
et al. (2016). The dopamine D1 receptor gene is associated with negative
schizotypy in a non-clinical sample. Psychiatry Res. 235, 213–214. doi:
10.1016/j.psychres.2015.11.051
Hahn, C.-G., Wang, H.-Y., Cho, D.-S., Talbot, K., Gur, R. E., Berrettini, W.
H., et al. (2006). Altered neuregulin 1-erbB4 signaling contributes to NMDA
receptor hypofunction in schizophrenia. Nat. Med. 12, 824–828. doi: 10.1038/
nm1418
Hamshere, M. L., Green, E. K., Jones, I. R., Jones, L., Moskvina, V., Kirov, G.,
et al. (2009). Genetic utility of broadly defined bipolar schizoaffective disorder
as a diagnostic concept. Br. J. Psychiatry 195, 23–29. doi: 10.1192/bjp.bp.108.
061424
Harrison, P. J., and Weinberger, D. R. (2005). Schizophrenia genes, gene
expression, and neuropathology: on the matter of their convergence. Mol.
Psychiatry 10, 40–68. doi: 10.1038/sj.mp.4001558
Hashimoto, R., Noguchi, H., Hori, H., Nakabayashi, T., Suzuki, T., Iwata, N., et al.
(2010). A genetic variation in the dysbindin gene (DTNBP1) is associated with
memory performance in healthy controls. World J. Biol. Psychiatry 11(2 Pt 2),
431–438. doi: 10.3109/15622970902736503
Heck, A., Fastenrath, M., Ackermann, S., Auschra, B., Bickel, H., Coynel,
D., et al. (2014). Converging genetic and functional brain imaging
evidence links neuronal excitability to working memory, psychiatric disease,
and brain activity. Neuron 81, 1203–1213. doi: 10.1016/j.neuron.2014.
01.010
Hennah, W., Varilo, T., Kestilä, M., Paunio, T., Arajärvi, R., Haukka, J., et al.
(2003). Haplotype transmission analysis provides evidence of association for
DISC1 to schizophrenia and suggests sex-dependent effects. Hum. Mol. Gen.
12, 3151–3159. doi: 10.1093/hmg/ddg341
Hossein, F. S., and Folsom, T. D. (2011). The role of fragile X mental retardation
protein in major mental disorders. Neuropharmacology 60, 1221–1226. doi:
10.1016/j.neuropharm.2010.11.011
Itti, E., Gaw Gonzalo, I. T., Boone, K. B., Geschwind, D. H., Berman, N.,
Pawlikowska-Haddal, A., et al. (2003). Functional neuroimaging provides
evidence of anomalous cerebral laterality in adults with Klinefelter’s Syndrome.
Ann. Neurol. 54, 669–673. doi: 10.1002/ana.10735
Jones, L. A., Cardno, A. G., Murphy, K. C., Sanders, R. D., Gray, M. Y., McCarthy,
G., et al. (2000). The Kings Schizotypy Questionnaire as a quantitative measure
of schizophrenia liability. Schizophr. Res. 45, 213–221. doi: 10.1016/S0920-
9964(99)00183-8
Kelemen, O., Kovács, T., and Kéri, S. (2013). Contrast, motion, perceptual
integration, and neurocognition in schizophrenia: the role of fragile-X
related mechanisms. Progress Neurol. 46, 92–97. doi: 10.1016/j.pnpbp.2013.
06.017
Kendler, K. S., and Hewitt, J. (1992). The structure of self-report schizotypy in
twins. J. Pers. Disord. 6, 1–17. doi: 10.1521/pedi.1992.6.1.1
Frontiers in Psychology | www.frontiersin.org 16 November 2016 | Volume 7 | Article 1769
Walter et al. Genetics and Schizotypy Review
Kendler, K. S., McGuire, M., Gruenberg, A. M., O’Hare, A. O., Spellman, M., and
Walsh, D. (1993). The Roscommon Family Study III. Schizophrenia-related
disorders in relatives. Arch. Gen. Psychiatry 50, 781–788.
Kendler, K. S., McGuire, M., Gruenberg, A. M., Walsh, D., and Virginia, V. (1995).
Schizotypal symptoms and signs in the Roscommon Family Study. Arch. Gen.
Psychiatry 52, 296–303. doi: 10.1001/archpsyc.1995.03950160046009
Kerby, D. S., and Dawson, B. L. (1994). Autistic features, personality and adaptive
behaviour in males with fragile X syndrome and no autism. Am. J. Men.
Retardation 98, 455–462.
Kheirollahi, M., Kazemi, E., and Ashouri, S. (2016). Brain-
derived neurotrophic factor gene Val66Met polymorphism
and risk of schizophrenia: a meta-analysis of case–control
studies. Cell. Mol. Neurobiol. 36, 1–10. doi: 10.1007/s10571-015-
0229-z
Kovács, T., Kelemen, O., and Kéri, S. (2013). Decreased fragile X mental
retardation protein (FMRP) is associated with lower IQ and earlier illness
onset in patients with schizophrenia. Psychiatry Res. 210, 690–693. doi:
10.1016/j.psychres.2012.12.022
Kwapil, T. R., Gross, G. M., Silvia, P. J., and Barrantes-Vidal, N. (2013). Prediction
of psychopathology and functional impairment by positive and negative
schizotypy in the Chapmans’ ten-year longitudinal study. J. Abnorm. Psychol.
122, 807–815. doi: 10.1037/a0033759
Laity, J. H., Lee, B. M., and Wright, P. E. (2001). Zinc finger proteins: new insights
into structural and functional diversity. Curr. Opin. Struct. Biol. 11, 39–46. doi:
10.1016/S0959-440X(00)00167-6
Lataster, J., Collip, D., Ceccarini, J., Hernaus, D., Haas, D., Booij, L., et al. (2014).
Familial liability to psychosis is associated with attenuated dopamine stress
signaling in ventromedial prefrontal cortex. Schizophr. Bull. 40, 66–77. doi:
10.1093/schbul/sbs187
Law, A. J., Kleinman, J. E., Weinberger, D. R., and Weickert, C. S. (2007). Disease-
associated intronic variants in the ErbB4 gene are related to altered ErbB4
splice-variant expression in the brain in schizophrenia. Hum. Mol. Genet. 16,
129–141. doi: 10.1093/hmg/ddl449
Leach, E. L., Hurd, P. L., and Crespi, B. J. (2013). Schizotypy, cognitive
performance, and genetic risk for schizophrenia in a non-clinical population.
Pers. Individ. Dif. 55, 334–338. doi: 10.1016/j.paid.2013.03.010
Leach, E. L., Prefontaine, G., Hurd, P. L., and Crespi, B. J. (2014). The
imprinted gene LRRTM1 mediates schizotypy and handedness in a nonclinical
population. J. Hum. Genet. 59, 332–336. doi: 10.1038/jhg.2014.30
Lenzenweger, M. F. (2006). Schizotypy an organising framework for
schizoprhenia research. Curr. Dir. Psychol. Sci. 15, 162–167. doi:
10.1111/j.1467-8721.2006.00428.x
Lenzenweger, M. F. (2013). Thinking clearly about the endophenotype-
intermediate phenotype-biomarker distinctions in developmental
psychopathology research. Dev. Psychopathol. 25(4 Pt 2), 1347–1357. doi:
10.1017/S0954579413000655
Levinson, D. F., Holmans, P., Straub, R. E., Owen,M. J.,Wildenauer, D. B., Gejman,
P. V., et al. (2000).Multicenter linkage study of schizophrenia candidate regions
on chromosomes 5q, 6q, 10p, and 13q: schizophrenia linkage collaborative
group III. Am. J. Hum. Genet. 67, 652–663. doi: 10.1086/303041
Li, B., Woo, R.-S., Mei, L., and Malinow, R. (2007). ErbB4, a receptor of
the schizophrenia-linked protein neuregulin-1, controls glutamatergic
synapse maturation and plasticity. Neuron 54, 583–597. doi:
10.1016/j.neuron.2007.03.028
Lien, Y.-J., Tsuang, H.-C., Chiang, A., Liu, C.-M., Hsieh, M. H., Hwang, T.-
J., et al. (2010). The multidimensionality of schizotypy in nonpsychotic
relatives of patients with schizophrenia and its applications in ordered subsets
linkage analysis of schizophrenia. Am. J. Med. Genet. B 153B, 1–9. doi:
10.1002/ajmg.b.30948
Linney, Y. M., Murray, R. M., Peters, E. R., MacDonald, A. M., Rijsdijk, F., and
Sham, P. C. (2003). A quantitative genetic analysis of schizotypal personality
traits. Psychol. Med. 33, 803–816. doi: 10.1017/S0033291703007906
Liu, H., Heath, S. C., Sobin, C., Roos, J. L., Galke, B. L., Blundell, M. L., et al.
(2002). Genetic variation at the 22q11 PRODH2/DGCR6 locus presents an
unusual pattern and increases susceptibility to schizophrenia. Proc. Natl. Acad.
Sci. U. S. A. 99, 3717–3722. doi: 10.1073/pnas.042700699
Ma, X., Sun, J., Yao, J., Wang, Q., Hu, X., Deng, W., et al. (2007). A quantitative
association study between schizotypal traits and COMT, PRODH and BDNF
genes in a healthy Chinese population. Psychiatry Res. 153, 7–15. doi:
10.1016/j.psychres.2007.02.003
Macar, C., Bates, T. C., Heath, A. C., Martin, N. G., and Ettinger, U. (2012).
Substantial genetic overlap between schizotypy and neuroticism: a twin study.
Behav. Genet. 42, 732–742. doi: 10.1007/s10519-012-9558-6
Mahon, K., Perez-Rodriguez, M. M., Gunawardane, N., and Burdick, K.
E. (2013). Dimensional endophenotypes in bipolar disorder: affective
dysregulation and psychosis proneness. J. Affect. Disord. 151, 695–701. doi:
10.1016/j.jad.2013.08.003
Martin, A. K., Robinson, G., Reutens, D., and Mowry, B. (2015). Clinical and
parental age characteristics of rare copy number variant burden in patients with
schizophrenia.Am. J. Med. Genet. B. Neuropsychiatr. Genet. 168B, 374–382. doi:
10.1002/ajmg.b.32321
Mason, O. J. (2015). The assessment of schizotypy and its clinical relevance.
Schizophr. Bull. 41, S374–S385. doi: 10.1093/schbul/sbu194
Mata, I., Gilvarry, C. M., Jones, P. B., Lewis, S. W., Murray, R. M., and Sham, P. C.
(2003). Schizotypal personality traits in nonpsychotic relatives are associated
with positive symptoms in psychotic probands. Schizophr. Bull. 29, 273–283.
doi: 10.1093/oxfordjournals.schbul.a007004
Mata, I., Sham, P. C., Gilvarry, C. M., Jones, P. B., Lewis, S. W., and Murray, R. M.
(2000). Childhood schizotypy and positive symptoms in schizophrenic patients
predict schizotypy in relatives. Schizophr. Res. 44, 129–136. doi: 10.1016/S0920-
9964(99)00222-4
McGurk, S. R., Mueser, K. T., Mischel, R., Adams, R., Harvey, P. D.,
McClure, M. M., et al. (2013). Vocational functioning in schizotypal
and paranoid personality disorders. Psychiatry Res. 210, 498–504. doi:
10.1016/j.psychres.2013.06.019
Michealraj, K. A., Jatana, N., Jafurulla, Narayanan, L., Chattopadhyay, A., and
Thelma, B. K. (2014). Functional characterization of rare variants in human
dopamine receptor D4 gene by genotype-phenotype correlations. Neuroscience
262, 176–189. doi: 10.1016/j.neuroscience.2013.12.059
Miller, P., Byrne, M., Hodges, A. N. N., Lawrie, S. M., David, G., Owens, C.,
et al. (2002). Schizotypal components in people at high risk of developing
schizophrenia: early findings from the Edinburgh High-Risk Study. Br. J.
Psychiatry 180, 179–184. doi: 10.1192/bjp.180.2.179
Monks, S., Niarchou, M., Davies, A. R., Walters, J. T. R., Williams,
N., Owen, M. J., et al. (2014). Further evidence for high rates of
schizophrenia in 22q11.2 deletion syndrome. Schizophr. Res. 153, 231–236. doi:
10.1016/j.schres.2014.01.020
Montag, C., Hall, J., Plieger, T., Felten, A., Markett, S., Melchers, M.,
et al. (2015). The DRD3 Ser9Gly polymorphism, machiavellianism, and its
link to schizotypal personality. J. Neurosci. Psychol. Econ. 8, 48–57. doi:
10.1037/npe0000034
Mors, O., Mortensen, P. B., and Ewald, H. (2001). No evidence of increased risk
for schizophrenia or bipolar affective disorder in persons with aneuploidies of
the sex chromosomes. Psychol. Med. 31, 425–430. doi: 10.1017/S0033291701
003476
Nelson, M. T., Seal, M. L., Pantelis, C., and Phillips, L. J. (2013). Evidence
of a dimensional relationship between schizotypy and schizophrenia:
a systematic review. Neurosci. Biobehav. Rev. 37, 317–327. doi:
10.1016/j.neubiorev.2013.01.004
Nguyen, G. H., Bouchard, J., Boselli, M. G., Tolstoi, L. G., Keith, L., Baldwin, C.,
et al. (2003). DNA stability and schizophrenia in twins.Am. J. Med. Genet. 120B,
1–10. doi: 10.1002/ajmg.b.20010
Nordentoft, M., Thorup, A., Petersen, L., Øhlenschlæger, J., Melau, M.,
Christensen, T. Ø., et al. (2006). Transition rates from schizotypal disorder
to psychotic disorder for first-contact patients included in the OPUS trial.
A randomized clinical trial of integrated treatment and standard treatment.
Schizophr. Res. 83, 29–40. doi: 10.1016/j.schres.2006.01.002
Ohi, K., Hashimoto, R., Nakazawa, T., Okada, T., Yasuda, Y., Yamamori, H.,
and Takeda, M. (2012). The p250GAP gene is associated with risk for
schizophrenia and schizotypal personality traits. PLoS ONE 7:e35696. doi:
10.1371/journal.pone.0035696
Park, Y., and Waldman, I. D. (2014). Influence of the COMT val108/158met
polymorphism on continuous performance task indices. Neuropsychologia 61,
45–55. doi: 10.1016/j.neuropsychologia.2014.06.008
Petryshen, T. L., Middleton, F. A., Tahl, A. R., Rockwell, G. N., Purcell, S.,
Aldinger, K. A., et al. (2005). Genetic investigation of chromosome 5q GABAA
Frontiers in Psychology | www.frontiersin.org 17 November 2016 | Volume 7 | Article 1769
Walter et al. Genetics and Schizotypy Review
receptor subunit genes in schizophrenia. Mol. Psychiatry 10, 1074–1088. doi:
10.1038/sj.mp.4001739
Pimm, J., McQuillin, A., Thirumalai, S., Lawrence, J., Quested, D., Bass, N., et al.
(2005). The Epsin 4 gene on chromosome 5q, which encodes the clathrin-
associated protein enthoprotin, is involved in the genetic susceptibility to
schizophrenia. Am. J. Hum. Genet. 76, 902–907. doi: 10.1086/430095
Porcelli, S., Lee, S. J., Han, C., Patkar, A. A., Serretti, A., and Pae, C. U. (2015).
CACNA1C gene and schizophrenia:a case-control and pharmacogenetic study.
Psychiatry Genet. 25, 163–167. doi: 10.1097/YPG.0000000000000092
Prasad, S. E., Howley, S., and Murphy, K. C. (2008). Candidate genes and the
behavioral phenotype in 22q11.2 deletion syndrome. Dev. Disabil. Res. Rev. 14,
26–34. doi: 10.1002/ddrr.5
Pulay, A. J., Stinson, F. S., Dawson, D. A., Goldstein, R. B., Chou, S. P., Huang,
B., et al. (2009). Prevalence, correlates, disability, and comorbidity of DSM-IV
Schizotypal Personality Disorder. Prim. Care Companion J. Clin. Psychiatry 11,
53–67. doi: 10.4088/PCC.08m00679
Raine, A. (2006). Schizotypal personality: neurodevelopmental and
psychosocial trajectories. Annu. Rev. Clin. Psychol. 2, 291–326. doi:
10.1146/annurev.clinpsy.2.022305.095318
Ramsay, H., Kelleher, I., Flannery, P., Clarke, M. C., Lynch, F., Harley,
M., et al. (2013). Relationship between the COMT-Val158Met and BDNF-
Val66Met polymorphisms, childhood trauma and psychotic experiences
in an adolescent general population sample. PLoS ONE 8:e79741. doi:
10.1371/journal.pone.0079741
Reiss, A. L., Eliez, S., Schmitt, J. E., Patwardhan, A., and Haberecht, M. (2000).
Brain imaging in neurogenetic conditions: realizing the potential of behavioral
neurogenetics research.Ment. Retard. Dev. Disabil. Res. Rev. 6, 186–197.
Reiss, A. L., Hagerman, R. J., Vinogradov, S., Abrams, M., and King, R. J. (1988).
Psychiatric disability in female carriers of the fragile X chromosome. Arch. Gen.
Psychiatry 45, 25–30. doi: 10.1001/archpsyc.1988.01800250029005
Roussos, P., Bitsios, P., Giakoumaki, S. G., McClure, M. M., Hazlett, E. A., New,
A. S., et al. (2013). CACNA1C as a risk factor for schizotypal personality
disorder and schizotypy in healthy individuals. Psychiatry Res. 206, 122–123.
doi: 10.1016/j.psychres.2012.08.039
Roussos, P., Giakoumaki, S. G., Georgakopoulos, A., Robakis, N. K., and Bitsios, P.
(2011). The CACNA1C and ANK3 risk alleles impact on affective personality
traits and startle reactivity but not on cognition or gating in healthy males.
Bipolar Disord. 13, 250–259. doi: 10.1111/j.1399-5618.2011.00924.x
Salokangas, R. K. R., and McGlashan, T. H. (2008). Early detection and
intervention of psychosis. A review. Nordic J. Psychiatry 62, 92–105. doi:
10.1080/08039480801984008
Schneider, M., Van der Linden, M., Menghetti, S., Debbané, M., and Eliez,
S. (2015). Negative and paranoid symptoms are associated with negative
performance beliefs and social cognition in 22q11.2 deletion syndrome. Early
Interv. Psychiatry. doi: 10.1111/eip.12224. [Epub ahead of print].
Schürhoff, F., Szöke, A., Chevalier, F., Roy, I., Méary, A., Bellivier, F., et al. (2007).
Schizotypal dimensions: an intermediate phenotype associated with the COMT
high activity allele. Am. J. Med. Genet. B 144, 64–68. doi: 10.1002/ajmg.b.
30395
Seeman,M. V, and Seeman, P. (2014). Is schizophrenia a dopamine supersensitivity
psychotic reaction. Prog. Neuropsychopharmacol. Biol. Psychiatry 48, 155–160.
doi: 10.1016/j.pnpbp.2013.10.003
Smallman, R. P., Barkus, E., Azadbakht, H., Embleton, K. V., Haroon, H. A.,
Lewis, S. W., et al. (2014). MRI diffusion tractography study in individuals
with schizotypal features: a pilot study. Psychiatry Res. 221, 49–57. doi:
10.1016/j.pscychresns.2013.10.006
Smyrnis, N., Avramopoulos, D., Evdokimidis, I., Stefanis, C. N., Tsekou, H., and
Stefanis, N. C. (2007). Effect of schizotypy on cognitive performance and
its tuning by COMT val158 met genotype variations in a large population
of young men. Biol. Psychiatry 61, 845–853. doi: 10.1016/j.biopsych.2006.
07.019
Sobesky, W. E., Hull, C. E., and Hagerman, R. J. (1994). Symptoms of schizotypal
personality disorder in fragile X women. J. Am. Acad. Child Adolesc. Psychiatry
33, 247–255. doi: 10.1097/00004583-199402000-00014
Solanki, R. K., Swami, M. K., Singh, P., and Gupta, S. (2012). Identification of
vulnerability among first-degree relatives of patients with schizophrenia. East
Asian Arch. Psychiatry 22, 118–125.
Stefanis, N. C., Hatzimanolis, A., Avramopoulos, D., Smyrnis, N., Evdokimidis,
I., Stefanis, C. N., et al. (2013). Variation in psychosis gene ZNF804A
is associated with a refined schizotypy phenotype but not neurocognitive
performance in a large young male population. Schizophr. Bull. 39, 1252–1260.
doi: 10.1093/schbul/sbs110
Stefanis, N. C., Hatzimanolis, A., Smyrnis, N., Avramopoulos, D., Evdokimidis, I.,
van Os, J., et al. (2011). Schizophrenia candidate gene ERBB4: covert routes of
vulnerability to psychosis detected at the population level. Schizophr. Bull. 39,
349–357. doi: 10.1093/schbul/sbr169
Stefanis, N. C., Trikalinos, T. A., Avramopoulos, D., Smyrnis, N., Evdokimidis, I.,
Ntzani, E. E., et al. (2008). Association of RGS4 variants with schizotypy and
cognitive endophenotypes at the population level. Behav. Brain Funct. 4:46. doi:
10.1186/1744-9081-4-46
Stefanis, N. C., Trikalinos, T. A., Avramopoulos, D., Smyrnis, N., Evdokimidis,
I., Ntzani, E. E., et al. (2007). Impact of schizophrenia candidate genes
on schizotypy and cognitive endophenotypes at the population level. Biol.
Psychiatry 62, 784–792. doi: 10.1016/j.biopsych.2006.11.015
Straub, R. E., Jiang, Y., MacLean, C. J., Ma, Y., Webb, B. T., Myakishev, M. V., et al.
(2002). Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of
themouse dysbindin gene, is associated with schizophrenia.Am. J. Hum. Genet.
71, 337–348. doi: 10.1086/341750
Sun, Y., Hu, D., Liang, J., Bao, Y.-P., Meng, S.-Q., Lu, L., et al. (2015).
Association between variants of zinc finger genes and psychiatric disorders:
systematic review and meta-analysis. Schizophr. Res. 162, 124–137. doi:
10.1016/j.schres.2015.01.036
Talbot, K., Cho, D. S., Ong, W. Y., Benson, M., Han, L. Y., Kazi, H., et al. (2006).
Dysbindin-1 is a synaptic and microtubular protein that binds brain snapin.
Hum. Mol. Genet. 15, 3041–3054. doi: 10.1093/hmg/ddl246
Talbot, K., Eidem, W. L., Tinsley, C. L., Benson, M. A., Thompson, E. W., Smith,
R. J., et al. (2004). Dysbindin-1 is reduced in intrinsic, glutamatergic terminals
of the hippocampal formation in schizophrenia. J. Clin. Invest. 113, 1353–1363.
doi: 10.1172/JCI200420425
Taurisano, P., Romano, R., Mancini, M., Giorgio, A., Di Antonucci, L. A., Fazio, L.,
et al. (2014). Prefronto-striatal physiology is associated with schizotypy and is
modulated by a functional variant of DRD2. Front. Behav. Neurosci. 8:235. doi:
10.3389/fnbeh.2014.00235
Tochigi, M., Zhang, X., Ohashi, J., Hibino, H., Otowa, T., Rogers, M.,
et al. (2006). Association study of the dysbindin (DTNBP1) gene in
schizophrenia from the Japanese population. Neurosci. Res. 56, 154–158. doi:
10.1016/j.neures.2006.06.009
Tosato, S., Ruggeri, M., Bonetto, C., Bertani, M., Marrella, G., Lasalvia,
A., et al. (2007). Association study of dysbindin gene with clinical and
outcome measures in a representative cohort of Italian schizophrenic
patients. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 144B, 647–659. doi:
10.1002/ajmg.b.30484
Tsiouris, J. A., and Brown, W. T. (2004). Neuropsychiatric symptoms of Fragile X
Syndrome. CNS Drugs 18, 687–703. doi: 10.2165/00023210-200418110-00001
Tsuang, M. (2000). Schizophrenia: genes and environment. Biol. Psychiatry 47,
210–220. doi: 10.1016/S0006-3223(99)00289-9
Van Rijn, S., Aleman, A., De Sonneville, L., and Swaab, H. (2009). Cognitive
mechanisms underlying disorganization of thought in a genetic syndrome
(47,XXY). Schizophr. Res. 112, 91–98. doi: 10.1016/j.schres.2009.04.017
Van Rijn, S., Aleman, A., Swaab, H., and Kahn, R. (2006). Klinefelter’s syndrome
(karyotype 47, XXY) and schizophrenia-spectrum pathology. Br. J. Psychiatry
189, 459–460. doi: 10.1192/bjp.bp.105.008961
Venables, P., Wilkins, S., Mitchell, D., Raine, A., and Bailes, K. (1990). A scale
for the measurement of schizotypy. Pers. Individ. Dif. 11, 481–495. doi:
10.1016/0191-8869(90)90061-U
Verhoeven, W. M., and Egger, J. I. M. (2011). Schizotypy: Key feature
of Klinefelter’s syndrome? BMJ Case Rep. 2011:bcr0520114279. doi:
10.1136/bcr.05.2011.4279
Vilella, E., Costas, J., Sanjuan, J., Guitart, M., De Diego, Y., Carracedo, A., et al.
(2008). Association of schizophrenia with DTNBP1 but not with DAO, DAOA,
NRG1 and RGS4 nor their genetic interaction. J. Psychiatr. Res. 42, 278–288. doi:
10.1016/j.jpsychires.2007.02.005
Vollema, M. G., Sitskoorn, M. M., Appels, M. C., and Kahn, R. S. (2002).
Does the Schizotypal Personality Questionnaire reflect the biological-genetic
Frontiers in Psychology | www.frontiersin.org 18 November 2016 | Volume 7 | Article 1769
Walter et al. Genetics and Schizotypy Review
vulnerability to schizophrenia? Schizophr. Res. 54, 39–45. doi: 10.1016/S0920-
9964(01)00350-4
Waldeck, T. L., and Miller, L. S. (2000). Social skills deficits in schizotypal
personality disorder. Psychiatry Res. 93, 237–246. doi: 10.1016/S0165-
1781(00)00122-0
Williams, M. B. (1993). The Psychometric Assessment of Schizotypal Personality.
London: University of London.
Wing, J. K., Cooper, J. E., and Sartorius, N. (1974). The Measurement and
Classification of Psychiatric Symptoms. Cambridge: Cambridge University
Press.
Woodward, N. D., Cowan, R. L., Park, S., Ansari, M. S., Baldwin, R. M., Li, R., et al.
(2011). Correlation of individual differences in schizotypal personality traits
with amphetamine-induced dopamine release in striatal and extrastriatal brain
regions. Am. J. Psychiatry 168, 418–426. doi: 10.1176/appi.ajp.2010.10020165
World Health Organization. (1992). The International Personality Disorder
Examination (IPDE). Geneva: World Health Organization.
Xu, B., Woodroffe, A., Rodriguez-Murillo, L., Roos, J. L., van Rensburg, E. J.,
Abecasis, G. R., et al. (2009). Elucidating the genetic architecture of familial
schizophrenia using rare copy number variant and linkage scans. Proc. Natl.
Acad. Sci. U.S.A. 106, 16746–16751. doi: 10.1073/pnas.0908584106
Yang, H. C., Liu, C. M., Liu, Y. L., Chen, C. W., Chang, C. C., Fann, C. S. J.,
et al. (2013). The DAO gene is associated with schizophrenia and interacts with
other genes in the Taiwan Han Chinese population. PLoS ONE 8:e60099. doi:
10.1371/journal.pone.0060099
Yaralian, P. S., Raine, A., Lencz, T., Hooley, J. M., Bihrle, S. E., Mills, S., et al.
(2000). Elevated levels of cognitive-perceptual deficits in individuals with a
family history of schizophrenia spectrum disorders. Schizophr. Res. 46, 57–63.
doi: 10.1016/S0920-9964(99)00239-X
Yasuda, Y., Hashimoto, R., Ohi, K., Fukumoto, M., Umeda-Yano, S.,
Yamamori, H., et al. (2011). Impact on schizotypal personality trait
of a genome-wide supported psychosis variant of the ZNF804A
gene. Neurosci. Lett. 495, 216–220. doi: 10.1016/j.neulet.2011.
03.069
Zammit, S., Hamshere, M., Dwyer, S., Georgiva, L., Timpson, N., Moskvina,
V., et al. (2014). A population-based study of genetic variation and
psychotic experiences in adolescents. Schizophr. Bull. 40, 1254–1262. doi:
10.1093/schbul/sbt146
Zhu, M., Liu, T., Zhang, J., Jia, S., Tang, W., and Luo, Y. (2014). Association
Between rs1344706 of ZNF804A and Schizophrenia: a meta-analysis.
Genomics Proteomics Bioinformatics 12, 292–296. doi: 10.1016/j.gpb.2014.
10.005
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Walter, Fernandez, Snelling and Barkus. This is an open-access
article distributed under the terms of the Creative Commons Attribution License (CC
BY). The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Psychology | www.frontiersin.org 19 November 2016 | Volume 7 | Article 1769
